This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Turner, H. E. Articles by Wass, J. A. H. Search for Related Content PubMed PubMed Citation Articles by Turner, H. E. Articles by Wass, J. A. H.

Angiogenesis in Endocrine Tumors

Department of Endocrinology (H.E.T., J.A.H.W.), Churchill Hospital, Oxford OX3 7LJ, United Kingdom; Molecular Angiogenesis Group (A.L.H.), Imperial Cancer Research Fund, Institute of Molecular Medicine, John Radcliffe Hospital, OX3 9DU Oxford, United Kingdom; and Davis Research Institute (S.M.), Cedars Sinai Hospital, Los Angeles, California 90048

Correspondence: Address all correspondence and requests for reprints to: Dr. Helen E. Turner, Department of Endocrinology, Churchill Hospital, Old Road, Oxford OX3 7LJ, United Kingdom. E-mail: jenny.Thomson{at}orh.nhs.uk

	Abstract

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

 
Angiogenesis is the process of new blood vessel development from preexisting vasculature. Although vascular endothelium is usually quiescent in the adult, active angiogenesis has been shown to be an important process for new vessel formation, tumor growth, progression, and spread. The angiogenic phenotype depends on the balance of proangiogenic growth factors such as vascular endothelial growth factor (VEGF) and inhibitors, as well as interactions with the extracellular matrix, allowing for endothelial migration. Endocrine glands are typically vascular organs, and their blood supply is essential for normal function and tight control of hormone feedback loops. In addition to metabolic factors such as hypoxia, the process of angiogenesis is also regulated by hormonal changes such as increased estrogen, IGF-I, and TSH levels.

By measuring microvascular density, differences in angiogenesis have been related to differences in tumor behavior, and similar techniques have been applied to both benign and malignant endocrine tumors with the aim of identification of tumors that subsequently behave in an aggressive fashion.

In contrast to other tumor types, pituitary tumors are less vascular than normal pituitary tissue, although the mechanism for this observation is not known. A relationship between angiogenesis and tumor size, tumor invasiveness, and aggressiveness has been shown in some pituitary tumor types, but not in others. There are few reports on the role of microvascular density or angiogenic factors in adrenal tumors. The mechanism of the vascular tumors, which include adrenomedullary tumors, found in patients with Von Hippel Lindau disease has been well characterized, and clinical trials of antiangiogenic therapy are currently being performed in patients with Von Hippel Lindau disease. Thyroid tumors are more vascular than normal thyroid tissue, and there is a clear correlation between increased VEGF expression and more aggressive thyroid tumor behavior and metastasis. Although parathyroid tissue induces angiogenesis when autotransplanted and PTH regulates both VEGF and MMP expression, there are few studies of angiogenesis and angiogenic factors in parathyroid tumors.

An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment.

I. Introduction

II. Mechanism of Angiogenesis

A. Proangiogenic growth factors

B. Measurement of angiogenesis

C. Influence of hormones on angiogenesis and VEGF

D. Inhibitors of angiogenesis

E. Extracellular matrix, invasion, and metalloproteinases

F. Importance of angiogenesis

III. Pituitary Tumors

A. Microvascular density of tumors

B. Pituitary vasculature

C. Angiogenesis in animal models of pituitary tumors

D. Angiogenic factors

E. Genes and regulation of angiogenesis

F. Matrix metalloproteinases

G. Therapeutic application of angiogenesis inhibitors

IV. Adrenal Tumors

A. Microvascular density of tumors

B. Angiogenic factors

C. Matrix metalloproteinases

D. Genes and regulation of angiogenesis

E. Therapeutic application of angiogenesis inhibitors

V. Thyroid Tumors

A. Microvascular density of tumors

B. Angiogenic factors

C. Matrix metalloproteinases

D. Therapeutic application of angiogenesis inhibitors

E. Genes and regulation of angiogenesis

VI. Parathyroid Tumors

A. Microvascular density of tumors

B. Angiogenic factors

C. Matrix metalloproteinases

D. Genes and regulation of angiogenesis

VII. Carcinoid Tumors

VIII. Gastrointestinal Neuroendocrine Tumors

IX. Conclusions

	I. Introduction

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

 
ANGIOGENESIS IS DEFINED as the development of new blood vessels from preexisting vessels, and it is a crucial process in normal physiology (1). Thus, angiogenesis plays an essential role in physiological processes such as embryonic development, wound healing, and the normal menstrual cycle (2, 3). It is however also an important pathogenic process in several diseases such as atherosclerosis (4), arthritis (5), diabetic retinopathy (6), and psoriasis (7).

A major interest has been the relationship of pathological angiogenesis and its role in tumor biology (8). On the basis of experiments that showed that tumors implanted into isolated perfused organs failed to develop, whereas the same tumors implanted within 6 mm of blood vessels not only induced angiogenesis but also both grew and metastasized (9, 10), Folkman (11) proposed that solid tumors are dependent on the process of angiogenesis for growth beyond a few millimeters in size and that increased tumor diameter required a corresponding increase in vascularization.

Angiogenesis (measured as tumor microvessel density) correlates with tumor behavior. In many human tumors, including breast, bladder, and stomach, increased angiogenesis has been shown to be associated with the development of metastases (12, 13), poor prognosis (14, 15), and reduced survival (16, 17).

Endocrine organs are very vascular, with fenestrated epithelium lining the blood vessels, which allows easy transfer of substances across the permeable vessel wall (18, 19). The blood supply is clearly essential for normal metabolic and endocrine functions. Complex feedback loops whereby differences in the serum concentration of various factors lead to alteration in hormonal secretion are essential for endocrine function. The necessity for rapid and tight regulation of these systems, frequently over a very small range of hormone concentrations, clearly requires an efficient blood supply. The purpose of this review is to explore current knowledge regarding angiogenesis in endocrine tumors.

Although the process of angiogenesis has been mainly studied in the context of malignant tumors, precancer has also been associated with increased angiogenic growth factor expression and increased vascularity when compared with nonneoplastic host tissue. Premalignant lesions are more vascular than normal tissue, and precarcinoma of the cervix and breast exhibit increased microvascular density (MVD) (20, 21, 22). Studies using RT-PCR and in situ hybridization (ISH) for the proangiogenic growth factor vascular endothelial growth factor (VEGF) in colonic tissues ranging from normal colon to invasive colorectal tumors show increased VEGF expression in the premalignant phase (23). Histologically, normal lobules derived from breast tissue harboring cancer are more angiogenic than lobules derived from breasts without cancer (24). Transgenic mice with an oncogene in the pancreatic ß-cells demonstrate increased angiogenesis in hyperplastic islets before development of frank neoplastic change (25). Inhibitors of angiogenesis such as angiostatin and endostatin reduce tumor growth if administered at this early stage, suggesting that increasing angiogenesis is important to tumor progression (26).

	II. Mechanism of Angiogenesis

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

 
Angiogenesis is a multistep process, involving both the endothelium and the extracellular matrix (1). After a stimulatory signal (such as a specific growth factor), activated endothelial cells release proteases (such as plasminogen activator), which lead to degradation of the extracellular matrix surrounding the vessel (27), followed by endothelial migration and proliferation. Endothelial cells are reorganized into a tubular structure, followed by fusion with other newly formed vessels, leading eventually to an anastomotic network (28).

The events that occur during development of an angiogenic phenotype are complex, involving stimulation by different proangiogenic growth factors and reduction in inhibitors of angiogenesis. The process involves an interaction between tumor cells, endothelial cells, macrophages, fibroblasts, and the extracellular matrix, all of which are capable of releasing factors influencing the angiogenesis mechanism. It is the net balance of proangiogenic factors and inhibitors of angiogenesis that determines the final angiogenic phenotype of the tumor.

Adult endothelial cells are usually quiescent, but may be stimulated to enter the cell cycle and develop into new capillaries. The switch concept describes the process whereby angiogenesis is activated (29). An understanding of the mechanism of this angiogenic switch in tumors may lead to further understanding of specific determinants of tumor behavior including invasion, malignancy, and metastasis. Studies in transgenic mice, in which tumor development progresses through distinct stages, have demonstrated that the switch to an angiogenic phenotype occurs at an early stage in tumor development and is potentially rate-limiting for subsequent tumor growth (25, 29).

Mechanisms subserving the angiogenic switch relate to a balance of proangiogenic and inhibitory stimuli. Angiogenesis inducers include VEGF and basic fibroblast growth factor (FGF-2), whereas more recently endogenous angiogenesis inhibitors have been described. These latter are often cleaved products of other larger proteins that are not themselves inhibitors. For example, angiostatin is a cleaved product of plasminogen, and endostatin arises from collagen XVIII. Control of proteases and the cleavage process is still not elucidated, but the system is usually effective in inhibiting angiogenesis, as exemplified in pancreatic islets in which VEGF and FGF expression is constitutive but angiogenesis does not normally occur (30). Negative regulators may be particularly important in endocrine organs that are very vascular, to maintain a quiescent endothelium, and rather than increased inducers of angiogenesis, down-regulation of inhibitor production may be required to activate the angiogenic switch (29) (Fig. 1).

View larger version (24K): [in this window] [in a new window]   FIG. 1. Diagram showing proposed balance hypothesis (derived from Ref.29 ).

FGFs were the first angiogenic factors discovered, and they are probably of importance when the tumor becomes large, degrades the extracellular matrix in which FGF is sequestered, and acts through the high-affinity cell-surface tyrosine kinase FGF receptors (FGFR-1 to FGFR-4) (for review, see Ref.33). There are currently 20 described distinct FGFs of which FGF-1, FGF-2, and to a lesser extent FGF-3, FGF-4, FGF-5, and FGF-7 have been shown to possess proangiogenic activity (33, 34). Alternate splicing of the FGFR genes and/or expression of the different FGFR genes themselves leads to different forms of FGFR expression and specificity for different FGFs (33).

VEGF mRNA is up-regulated in virtually every tumor type examined, and in all of these cases VEGF mRNA is invariably expressed in tumor cells (35, 36, 37, 38). Other experiments have shown that the stroma around the tumor may also be an important source of VEGF (39). Immunohistochemistry demonstrates VEGF expression not only in tumor cells but also in the vasculature of these tumors, showing that VEGF is secreted as a paracrine mediator that localizes in target cells (36, 40). High VEGF expression correlates with poor prognosis in breast cancer and non-small cell lung cancer (31, 40, 41).

After the discovery of VEGF, other VEGF-related genes have been identified, encoding placental growth factor and VEGF-B, -C, and -D (38). These demonstrate variable structural homology to VEGF but have different receptor specificities (Table 1). VEGF-B is mainly found in muscle and myocardium but not endothelial cells and signals through VEGF receptor (VEGFR)-1 (42, 43). VEGF-C and VEGF-D signal through the VEGFR-2 and VEGFR-3 to stimulate lymphangiogenesis (44, 45, 46, 47). All three VEGF receptors are characterized by seven extracellular Ig homology domains in which the second and third domains are essential for ligand binding and the fourth to seventh are essential for receptor dimerization (38, 48, 49). Signal transduction involves receptor dimerization and activation of tyrosine kinase (50). Knockout studies in mice demonstrate that Flt-1 (–/–) (VEGFR-1) mice die at embryonic d 8.5 due to disorganization and overgrowth of endothelial cells (51). KDR (–/–) (VEGFR-2) knockout mice are also lethal at embryonic d 8.5 due to the lack of blood vessel development as well as inadequate hemopoiesis (52). VEGFR-3-deficient embryos die due to defective vascular remodeling before lymphatic development (53).

VEGF signals through two tyrosine kinase receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR) (Table 1), expressed mainly on endothelial cells; VEGFR-2 is responsible for signaling, whereas VEGFR-1 may play a regulatory role (1). A third VEGF receptor (VEGFR-3) is found in lymphatic endothelium, which binds other members of the VEGF family (VEGF-C and VEGF-D) (58, 59, 60). Recombinant soluble VEGFR-1 or VEGFR-2 inhibits angiogenesis in the retina, corpus luteum, and tumors (61, 62, 63), whereas expression of a dominant negative VEGFR-2 mutant using a retrovirus inhibits signaling through the receptor and suppresses growth of tumors such as glioblastoma multiforme in vivo (64, 65). Expression of a soluble VEGFR-3 has been shown to inhibit lymphangiogenesis in mouse embryos (47).

The human VEGF gene is localized to 6p21.3, and alternative exon splicing generates four different isoforms of VEGF: VEGF 121, 165, 189, and 206 (66). Regulation of VEGF gene expression occurs via several different mechanisms, including hypoxia, growth factors, and cytokines (66). The hypoxic signal is mediated via hypoxia inducible factor (HIF)-1, a heterodimer consisting of a constitutively expressed HIF-1 ß-subunit, (HIF-1ß) and an oxygen and growth factor regulated HIF-1 -subunit (HIF-1). HIF-1 is usually unstable in the presence of oxygen and subject to oxygen-dependent ubiquination and proteasomal degradation, whereas during states of hypoxia, HIF-1 is stable (67). The dimer HIF-1 binds to the hypoxia response element (HRE) within the VEGF promoter and leads to VEGF transcription (68). Another transcription factor, HIF-2, also accumulates during hypoxia and binds to a ß-subunit to form an HIF-1 complex, activating HREs, leading to increased VEGF transcription (69, 70), and undergoing oxygen-dependent degradation. HREs are also found within genes of the glycolytic pathway and the erythropoietin gene leading to oxygen regulation of glycolysis and red cell formation (71). In vitro HIF-defective tumors do not show increased VEGF around areas of necrosis and are less vascularized (72).

Other proangiogenic growth factors and cytokines also up-regulate VEGF mRNA expression, including epidermal growth factor (EGF), TGF-ß, FGF, IL-1, and IGF-I (73, 74, 75, 76, 77). VEGF may therefore also act as a paracrine mediator for other angiogenic factors. Cell density also determines VEGF expression independent of the presence of hypoxia (78).

The angiopoietins are another family of angiogenic growth factors that signal through the Tie family of receptors (79). Ang-1 and Ang-2 are stimulatory and inhibitory ligands, respectively, at the Tie-2 receptor and important in the female reproductive cycle as well as tumor development (80, 81). Recent studies have demonstrated that the angiopoietins and VEGF in combination may fine-tune the process of angiogenesis (82).

A link between hormonal stimulation and increased angiogenesis has recently been elegantly demonstrated (83, 84) (Fig. 2) whereby castration-induced regression of prostate vasculature was reversed by testosterone-dependent angiogenic factors. Although this increase in angiogenesis occurred in the absence of androgen receptors on endothelial cells, the identity of these angiogenic factors responsive to increased testosterone is as yet unknown, but likely includes VEGF.

View larger version (24K): [in this window] [in a new window]   FIG. 2. Diagram showing proposed mechanism for hormonal regulation of angiogenesis in the prostate. [Reproduced with permission from J. Folkman: Endocrinology 139: 441–442, 1998 (84 ). © The Endocrine Society.]

Vascular density of different tumors has been assessed by counting vessels labeled using immunohistochemistry with antibodies to different endothelial markers on both frozen and paraffin-embedded sections. Antibodies that are most commonly used are directed against the endothelial antigens factor eight-related antigen (F8), CD31 (platelet endothelial cell adhesion molecule), CD34, and the lectin ulex europaeus agglutinin 1 (UEA1). These markers differ in their sensitivity for detection of endothelium (88, 89). CD31 and CD34 are the most sensitive and specific markers currently available for use on paraffin sections, although other markers may be easier to use because of practical difficulties with antigen retrieval (87). Different antibodies demonstrate varying sensitivities for detection of endothelium. F8 stains large vessels but does not label smaller microvessels (90). CD31 stains microvessels, but antigen loss can make this reagent unreliable in paraffin-embedded tissue; UEA1 stains all microvessels, but also stains the Golgi in some neoplastic cells (87, 88, 91). Choice of technique may therefore influence the results of MVD measurement.

The use of these markers reflects total vascular density, and new markers being developed are more specific for activated endothelium, but their disadvantage is that, at present, most are only effective when used on frozen tissue. They may, however, be useful to assess specific targets for therapy, e.g., new vessels or the degree of vascular remodeling. These include Tie 2/Tek, which recognizes an endothelial tyrosine kinase (92, 93); E-9, which recognizes endoglin, which is expressed on vascular cells from tumors and inflamed organs (94); and TEC-11, which recognizes a different epitope of endoglin (95). Tumor angiogenesis may also be measured in vivo by magnetic resonance imaging using a contrast agent targeted to the Vß3 integrin, which is more strongly expressed on blood vessels undergoing angiogenesis and may play a role in extracellular matrix adherence during angiogenesis (96). The use of the LH39 antibody recognizing an epitope found only in mature vessels and comparison with vascular counts using CD31, which recognizes both mature and newly formed vessels, allows a measurement of active vascular remodeling rather than a static vessel count. This vascular maturation index correlates well with tumor stage and prognosis in non-small cell lung and breast cancer (97, 98).

There are several methods for quantifying microvessel counts. The original technique described the selection of the most highly vascular areas (hot spots) and counting of individual microvessels (12). The rationale for locating the most vascular area hot spot is based on the fact that tumor behavior is likely to be related to the most vascular area of the tumor (87). Other described techniques are an overall semiquantitative grading technique, Chalkley counting using a microscope eyepiece containing a graticule containing 25 randomly positioned dots (99), and computerized image analysis (87, 100). Clearly the choice of quantification method introduces another important variable when using MVD as a reflection of angiogenesis.

The accuracy of these techniques depends mainly on the correct localization of the hot spot in addition to whether a representative block of tissue is chosen. Despite these potential problems, microvessel counts derived from all techniques have been shown to correlate with tumor prognosis and behavior (12, 15, 87).

C. Influence of hormones on angiogenesis and VEGF
The close relationship between endocrine function and angiogenesis is demonstrated during physiological processes such as the normal menstrual cycle, but also within pathological processes such as the regression in prostate vasculature after castration and the increase in vascularity of the thyroid gland during goiter development.

Table 2A summarizes the in vitro and in vivo effects of hormones on MVD/angiogenesis and/or VEGF production. Most hormones increase angiogenesis, except for glucocorticoids, which reduce VEGF expression.

In Graves’ disease, consistent with the stimulatory effect of TSH receptor antibodies on thyroid function itself, these antibodies also increase angiogenic factors (120). TSH stimulation of cultured thyrocytes was shown in a biological assay to cause endothelial cell proliferation (119).

D. Inhibitors of angiogenesis
The recognition of the therapeutic potential of inhibiting angiogenesis for treating tumors and other angiogenesis-dependent conditions has led to the study of several agents that act at different stages of the angiogenesis pathway (140, 141, 142). The control of physiological angiogenesis and maintenance of homeostasis have also led to the investigation of endogenous angiogenesis inhibitors. It has been recognized for many years that tumor (e.g., breast) metastases may remain dormant and also, curiously, that removal of a primary tumor may be followed by the rapid appearance of metastases.

Studies in a Lewis lung carcinoma mouse model have provided useful information on the mechanism of inhibition of angiogenesis. Removal of the primary tumor leads to rapid growth of tumor metastases (143). Serum and urine derived from mice bearing tumors were shown to inhibit endothelial proliferation (144). This endogenous inhibitor, termed angiostatin, was shown to be a cleaved product of plasminogen and inhibited angiogenesis and metastasis growth in vivo, although intact plasminogen lacked this activity (144). Further investigation of the behavior of dormant metastases showed that although cell proliferation of growing and dormant metastases was not different, metastases remained dormant due to a marked increase in apoptosis (145). Administration of angiostatin leads to inhibition of primary human and murine tumor growth in mice (146). The mechanism of generation of angiostatin from plasminogen has been investigated. Prostate carcinoma cells were shown to possess enzyme activity that cleaved plasminogen to active angiostatin (147, 148). The mechanism whereby angiostatin inhibits angiogenesis likely involves binding to ATP synthase in endothelial cells (149). Angiostatin administration using an adenovirus vector to a glioma tumor model (150), liposomes to a transgenic model of breast cancer (151), and sc to mice with colorectal tumors (152) leads to inhibition of tumor growth or reduction in metastases.

Endostatin, another cleavage product that acts as an endogenous angiogenesis inhibitor, was discovered from a murine hemangioendothelioma (153). This proteolytic fragment of collagen XVIII leads to inhibition of endothelial proliferation as well as increased tumor cell apoptosis leading to metastatic regression and dormancy of tumors.

Thrombospondin (TSP)1 and TSP2 are glycoproteins located within the extracellular matrix and possessing antiangiogenic activity (154). TSP1 suppresses vascular growth in vitro and in vivo, in both normal tissue and tumors (155). Expression of wt p53 has been associated with TSP1 expression providing a link between tumor suppressor gene expression and control of angiogenesis (156).

Of relevance to endocrine glands, somatostatin analogs (157, 158, 159, 160, 161) have been shown to possess inhibitory effects on angiogenesis. An endogenous substance, the 16-kDa fragment of prolactin (PRL), has also been demonstrated to possess angioinhibitory effects (162, 167).

1. Somatostatin analogs.
Using the chick chorioallantoic membrane (CAM), which allows visualization of changes in angiogenesis, the implantation of discs containing the somatostatin analog SMS 201-995 (octreotide) inhibited blood vessel growth in a dose-dependent fashion in vitro (157). Further studies using different somatostatin analogs demonstrated that the inhibition of angiogenesis was dependent on the structure of the molecule (158). Some analogs failed to inhibit angiogenesis. The mechanism for this effect, however, is not known but may involve inhibition of endothelial cell proliferation, although the precise somatostatin receptor involved is unknown. In vivo studies confirm that octreotide inhibits proliferation of human umbilical vein endothelial cells (HUVEC) (159). Studies of the antiangiogenic effect of somatostatin analogs in endocrine tumors have not been reported.

2. 16-kDa PRL and other members of the PRL/GH family (Table 2B).
The PRL molecule has been shown to give rise to a cleaved product, the 16-kDa fragment, which inhibits angiogenesis (167). There is evidence to suggest that the cleaving enzyme may be cathepsin D (168). The 16-kDa fragment has been shown in bioassays to have approximately 10% of the lactogenic effects of total PRL and 65% of the mitogenic activity (169). The full-length PRL molecule in contrast has been shown in the CAM assay to have proangiogenic effects, although it did not have demonstrable effects on angiogenesis in another in vivo assay (corneal angiogenesis) (162). These differences may be due to the maturity of the vessels studied.

Other members of the PRL/GH family and their respective cleaved fragments have also been shown in vitro and in vivo to exert opposing angioinhibitory and proangiogenic effects whereby the full-length hormone is proangiogenic and its N-terminal fragment is antiangiogenic (Table 2B). Further work is required to elucidate which of these effects are of physiological importance in vivo. However, the potential effect of an intrinsic dynamic balance of angiogenesis residing within a single hormone is an attractive concept for regulation of various physiological processes, such as human placental vascularization (162).

E. Extracellular matrix, invasion, and metalloproteinases
The matrix metalloproteinases (MMP) are a family of zinc-containing endopeptidases that are able to degrade the extracellular matrix and allow angiogenesis and tumor invasion, with each MMP acting on a different substrate (177, 178). MMP activity is balanced by tissue inhibitors of metalloproteinases (TIMPs) (179, 180, 181). MMP-2 and MMP-9 are both type IV collagenases that have been shown to be important in tumor invasion in vitro because they are able to break down basement membrane, in particular degrading collagen IV (178, 182). Elevated levels of circulating MMP-9 have been demonstrated in patients with breast cancer (183), and MMP-2 and/or MMP-9 release has been associated with tumor invasion and metastasis (184, 185, 186, 187, 188). Some authors have suggested that altered MMP-9 expression, in addition to MMP-11, characterizes epithelial tumors committed to malignant transformation, possibly relating to underlying genetic events that change the tumor phenotype to invasive (189).

MMP secretion is an important early process facilitating migration of endothelial cells through both the extracellular matrix and angiogenesis (190). In vitro studies have shown that microvascular endothelial cells do not constitutively secrete MMP-9; however, when exposed to an angiogenic stimulus (e.g., TNF-), MMP-9 production is up-regulated (191). Angiogenesis can be inhibited by endogenous TIMPs (192, 193) and also by administration of synthetic MMP inhibitors (e.g., KB-R7785) (194, 195). In addition to permissive effects on angiogenesis, MMP-9 also possesses angiostatin-converting enzyme activity, cleaving plasminogen to angiostatin, thus enhancing inhibition of angiogenesis (196), and potentially leading to a balance of proangiogenic activity and inhibition (29).

There are less data on the interaction between hormones and the MMPs (Table 2C). It is interesting to note that consistent with the down-regulatory effect of glucocorticoids on VEGF and angiogenesis, a reduction in MMP-9 expression with up-regulation of the enzyme TIMP-1 in the submucosa of the airways of patients with asthma treated with glucocorticoids has been demonstrated (197).

F. Importance of angiogenesis
The assessment and understanding of differences in angiogenesis in endocrine tumors may potentially allow accurate distinction of benign from malignant tumors (e.g., adrenal tumors and thyroid follicular neoplasms). In the pituitary gland, where it may be particularly difficult to predict subsequent tumor behavior, differences in angiogenesis may be helpful in assessing tumors more likely to recur or become aggressive and invasive. Because nonfunctioning tumors bear no useful tumor marker, it may be possible to use measurement of an angiogenic factor to determine whether complete tumor removal has been effective or whether tumor regrowth has occurred. Elucidation of angiogenesis mechanisms may help in understanding pathophysiology of hematogenous metastasis of follicular thyroid tumors and lymphatic spread of papillary tumors, or the very vascular phenotype of tumors in Von Hippel Lindau (VHL) syndrome, or why some pituitary tumors do not progress in size. It may be possible to use the measurement of angiogenesis to facilitate therapeutic decision making, for example which tumor is likely to behave aggressively and therefore require close follow-up or subsequent radiotherapy. There are many angiogenesis inhibitors in clinical trials (mainly phase I/II) (Table 3), and an understanding of angiogenesis may enable the use of angiogenesis inhibitors as therapy for endocrine tumors, e.g., synthetic MMP inhibitors for aggressive tumors or tyrosine kinase inhibitors to inhibit VEGF signaling.

	III. Pituitary Tumors

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

A. Microvascular density of tumors
1. Comparison of pituitary tumors with normal gland (Table 4).
Schechter (217) reported in 1972 that the parenchyma of pituitary tumors appeared less vascularized than autopsy specimens of normal tissue. Jugenburg et al. (218) used immunostaining for F8 to assess vascular density in a group of pituitary adenomas and carcinomas and showed that pituitary adenomas had lower vascular densities compared with the nontumorous pituitary.

View larger version (14K): [in this window] [in a new window]   FIG. 3. Comparison of vascular density between normal pituitary and different tumor types. A, Vascular density as measured by CD31 expression. B, Vascular density as measured by UEA1 staining. Normal, Normal anterior pituitary gland; Acro, GH-secreting tumors; MacPRL, macroprolactinomas; MicPRL, microprolactinomas; Cushing’s, ACTH-secreting tumors. Asterisk indicates mean value, and error bars indicate SEM. *, Statistically significant difference between MVD or normal gland and pituitary tumors, P < 0.05.

2. Angiogenesis and pituitary tumor behavior (Table 5).
Jugenburg et al. (218) showed an association between MVD as a measure of angiogenesis and pituitary tumor behavior; higher vascular densities were found in the rare pituitary carcinomas compared with benign adenomas. Another study used F8 to measure vascular density in 22 pituitary adenomas and reported that the highest vascular counts were found in FSH-expressing adenomas and lowest in GH-secreting tumors (224). Vascular density and tumor size or normal pituitary tissue were not compared.

We have shown a relationship between MVD and tumor size in prolactinomas and observed that microprolactinomas are less vascular than macroprolactinomas (Fig. 3). In contrast there was no difference between different-sized GH-secreting tumors (219). This finding is consistent with the notion that microprolactinomas represent a quite different pathological and clinical entity (227, 228) from macroprolactinomas, whereas different-sized GH-secreting tumors are part of the same disease spectrum. Additionally, MVD and serum PRL concentrations correlated positively, although no relationship with ACTH or GH secretion in ACTH-secreting or GH-secreting tumors was found (225). Bromocriptine or metyrapone treatment of patients with prolactinomas or Cushing’s disease, respectively, did not alter MVD of tumors compared with the MVD in tumors removed from patients who did not receive preoperative drug treatment. A recent study, however, has demonstrated that dopamine, signaling through endothelial cell D2 receptors, inhibits VEGF action, possibly by endocytosis of VEGFR-2 (229). Bromocriptine and quinpirole (D2 agonists) inhibit angiogenesis in a mouse ovarian tumor model (229). It might therefore be expected that bromocriptine or cabergoline should lead to angiogenesis inhibition in pituitary tumors. Two explanations for the difference between the animal model and human pituitary tumors are firstly that the typical patient undergoing surgery for a prolactinoma is resistant to, or intolerant of, the drug, and therefore a true comparison may not be valid. Alternatively, VEGF is secondary in importance to other factors (e.g., FGF-2) in stimulation of angiogenesis in pituitary tumors. In vitro studies of D2 agonists and prolactinomas will be helpful.

In terms of tumor behavior, MVD did not predict regrowth of nonfunctioning adenomas, suggesting that factors other than angiogenesis determine nonfunctioning tumor (NFA) recurrence (e.g., surgical technique). In contrast, MVD was related to tumor invasiveness and malignancy (218, 225). Higher vascular densities were found in those tumors showing local invasion of the cavernous sinus and bone and in rare pituitary cancers consistent with a relationship between aggressive pituitary tumor behavior and angiogenesis. Using a malignant pituitary tumor cell line (MGH3), PTHrP has been shown to increase new blood vessel formation in cell diffusion chambers implanted into rat sc tissue (136). Using in vitro techniques with bovine aortic endothelial cells in collagen gel and 8-bromo-cAMP, this study further demonstrated that the proangiogenic effect of PTHrP is unlikely to be directly due to increased endothelial cell proliferation or migration, but rather to capillary tube formation possibly via a cAMP pathway. Although PTHrP expression has only been shown in a metastatic pituitary GH-secreting tumor (230), it is known that PTHrP is produced by other malignant tumor types, and its role as a promoter of angiogenesis may therefore have more universal importance.

3. Relationship with cell proliferation (Table 6).
Assessment of cell proliferation using Ki-67 (a measurement of the proportion of cells within the cell cycle), showed no association between assessment of angiogenesis using MVD and cell proliferation (226), consistent with other tumor types, e.g., breast and colorectal cancer in which intratumoral MVD and Ki-67 labeling index were not related (86, 231, 232). A positive relationship was, however, observed between expression of the antiapoptotic protein bcl-2 and increasing MVD (226), suggesting that there may be an association between angiogenesis and apoptosis; a switch to an angiogenic phenotype and bcl-2 expression (preventing programmed cell death) may be early events in pituitary tumor pathogenesis. VEGF has been shown not only to stimulate endothelial cell proliferation but also to prolong endothelial cell survival by inducing expression of bcl-2 (233). Thus, angiogenesis appears to be related to the ability of pituitary tumor cells to survive, rather than their proliferative capacity.

View larger version (49K): [in this window] [in a new window]   FIG. 4. Diagram of vascular anatomy of pituitary gland. SHA, Superior hypophyseal artery; IHA, inferior hypophyseal artery. [Reproduced with permission from R. M. Bergland and R. B. Page: Science 204:18–24, 1979 (238 ). © American Association for the Advancement of Science.]

A number of controversies remain regarding the normal vascular supply to the anterior gland. Whether the blood supply to the anterior pituitary gland arises exclusively from the portal system is not entirely clear. Some authors also describe the presence of a loral artery, which arises from the anterior hypophyseal artery and enters the superior surface of the anterior lobe; in addition, they suggest that capsular arteries may also provide an arterial supply (237). Others disagree on the presence of a direct systemic source to the anterior gland (238). It is likely that the capsular arteries may supply a small number of cells in the anterior gland, but the predominant vascular supply to the normal adenohypophysis is portal in origin.

There are few studies assessing the source of the vascular supply to human pituitary adenomas. A neuroradiological study performed when angiography and pneumoencephalography were the usual imaging methods performed in the diagnosis of pituitary tumors demonstrated that at least a portion of the blood supply to tumors arose from the systemic vasculature. This was derived from branches of the internal carotid artery, most commonly the capsular and inferior hypophyseal arteries (239). A more recent neuroradiological study has extended these findings by using dynamic magnetic resonance imaging (240) and showed that enhancement of the posterior lobe could be demonstrated before the anterior lobe, as would be expected, but that macroadenoma enhancement also occurred before anterior lobe enhancement, suggesting that pituitary adenomas received a direct blood supply similar to the posterior lobe.

Intrasellar pressure in patients undergoing transsphenoidal surgery for pituitary adenoma is elevated, with a mean pressure of 25 mm Hg, compared with normal pressure of 10 mm Hg (241). This elevated pressure could obstruct the portal venous supply and therefore reduce the delivery of the normal controlling hypothalamic factors. Hyperprolactinemia observed in association with stalk compression syndrome could be related to compression of the portal blood supply. The lack of infarction or ischemia seen in the majority of tumors despite increased intrasellar pressure argues for an additional source of circulating blood. It is suggested that only a systemic arterial supply would allow maintained perfusion to the pituitary gland in this situation. The waveform of intrasellar pressure is pulsatile in two thirds of patients with tumors and in synchrony with the arterial waveform (241). The pressure was higher than venous pressures and may therefore be further evidence for a direct systemic arterial supply to pituitary tumors.

Two morphological studies also provide evidence for a direct arterial blood supply to pituitary adenomas (242, 243). Examination of the pituitary gland at autopsy of subjects with no known endocrine disorders demonstrated the presence of a microadenoma in 27%, and cannulation of the internal carotid artery and injection of dye demonstrated that two thirds of microadenomas had a direct extraportal blood supply (242). An electron microscopic examination of the vasculature within 16 prolactinomas showed that 13 contained arteries, but in contrast morphological evidence for arterial formation was not found in eight normal control pituitary glands (243). Interestingly, tumors with no arterial supply were described as small, although measurements were not provided.

These studies lend support to the notion that pituitary adenomas, in contrast to the normal anterior pituitary gland, receive a direct systemic arterial blood supply. In the liver (another organ with both a portal and direct arterial blood supply), the majority of metastases are supplied directly by the hepatic artery rather than the hepatic portal vein (244). A potential explanation for the relatively low vascular density of pituitary adenomas is that there has indeed been increased angiogenesis, but this has led to in-growth of blood vessels from the systemic circulation and the exclusion of the hypothalamic controlling factors found in the portal circulation.

Studies of the structure of pituitary tumor vasculature show the majority to be thin-walled fenestrated capillaries and give little clue as to the source of the vessel (systemic or portal). Some studies have suggested that ultrastructural changes (endothelial cell swelling and blebbing) seen in capillaries from pituitary tumor specimens may be due to tumor growth leading to compression of the long portal veins and ischemia (217). These studies have also suggested that tumor specimens were less well vascularized than the normal anterior pituitary gland derived from autopsy specimens and that the number of fenestrations may be reduced or even absent in pituitary tumors (217, 245). Altered parenchymatous basement membrane has been demonstrated in pituitary adenomas in which complete absence or fragmentation has been reported (246). This may be due to reduced synthesis or breakdown of the basement membrane by the tumor.

C. Angiogenesis in animal models of pituitary tumors
Studies of estrogen-induced lactotroph hyperplasia and tumor formation in rats with different susceptibility to estradiol have led to useful insights into the blood supply of pituitary tumors. Microspheres injected into the left side of the rat heart were trapped in the first capillary plexus they reached and did not reach the anterior pituitary gland (247). In contrast, rats with estradiol-induced lactotroph hyperplasia and PRL-secreting tumors exhibited numerous microspheres in the anterior pituitary gland, suggesting development of a direct arterial blood supply and confirmed as branches of vessels coursing through the dura (248). A direct arterial supply would be expected to potentiate lactotroph hyperplasia because the dopamine content of this source would be relatively low. Administration of bromocriptine reduced the effect of estradiol on both pituitary weight and serum PRL, as well as decreasing arteriogenesis (248). It was unclear, however, whether bromocriptine alters vasculature once formed. Hypotheses raised in this paper include the possibility that estradiol may induce vascular proliferation directly or via induction of an angiogenic factor such as FGF, or that estradiol suppressed the production of a substance that normally inhibits angiogenesis. Estrogen treatment also led to altered vascular ultrastructure coincident with tumorigenesis in estrogen-sensitive rats (249), in keeping with Schechter’s observation (217) in 1972 that tumors appeared less well-vascularized than the normal pituitary gland and blood flow per unit weight to pituitary tumors induced in rats by prolonged estrogen treatment is reduced (250).

D. Angiogenic factors
The angiogenic factors VEGF and FGF-2 were first isolated in the folliculostellate cells (FSC) of the pituitary gland.

1. FSC.
FSC were first described in the pituitary gland by Rinehart and Farquhar (251) and are characterized by their shape and long slender cytoplasmic processes. They can be identified using immunohistochemistry for S100 (252), although not all FSC immunostain positively for S100 (253). Although they compose follicles early in fetal development, they become stellate and form a reticular network throughout the adenohypophysis, connected to each other and adjacent endocrine cells by junctional complexes. It has been suggested that they play a role in compartmentalization of the anterior pituitary gland and that follicles are interconnected via FSC (254). Apart from a paracrine role, the presence of a Golgi apparatus and endoplasmic reticulum as well as phagocytic vesicles and lysosomal organelles is consistent with an active metabolic as well as a catabolic role (254, 255, 256, 257), and the production of cytokines such as IL-6 production is in keeping with a suggested homology with dendritic cells (253).

Ferrara et al. (258) studied follicular cell function after enzymatic dispersal of bovine anterior pituitary gland and in vitro culture. They demonstrated production of FGF-2 (259), a new growth factor—VEGF (260), and a possible angioinhibitory cytokine-LIF (222) from these cultures. The presence of FSC in pituitary adenomas has been investigated by different groups with conflicting results. We and others have shown that 35% (14 of 40) to 43% (61 of 93) of pituitary tumors contained S100-positive FSC (261, 262). In contrast, others find that FSC are rarely present in pituitary adenomas (263, 264). An unexplained finding is that GH-secreting tumors were most likely to contain FSC (261, 265). A universal finding is that FSC are more common in the normal anterior pituitary gland than in pituitary adenomas.

Animal models of pituitary tumors have demonstrated that FSC become activated during estrogen-induced prolactinoma formation in rats, with the appearance of cytoplasmic phagosomes and evidence of parenchymatous basement membrane degradation (257). This may be an important step in tumor progression, perhaps allowing angiogenesis and therefore tumor growth. The new technique of laser capture microdissection, which allows single cell isolation, will allow a clearer role for the FSC to be elucidated (266).

2. VEGF (Table 7A).
VEGF was first described in pituitary gland extracts (260). In animals, VEGF expression has been shown in rat, ovine, and mouse pituitary. Overexpression of VEGF in Fischer 344 rat pituitary glands and the GH3 cells has been demonstrated during estrogen-induced tumor angiogenesis (267, 273). These studies also demonstrated up-regulation of VEGFR-2 in estrogen-induced rat pituitary tumors and the presence of VEGFR-1 in sheep pituitary gland endothelial cells (267, 269).

View larger version (16K): [in this window] [in a new window]   FIG. 5. VEGF expression in a cohort of human pituitary tumors. Normal, Normal anterior pituitary gland; Acro, GH-secreting tumors; MacPRL, macroprolactinomas; MicPRL, microprolactinomas; Cushing’s, ACTH-secreting tumors. y-axis, Quantitative measure of VEGF labeling in nanoCuries per gram of tissue. Mean values are shown, with error bars indicating SEM. *, P < 0.05, for difference between normal gland and tumors; , P < 0.05, for difference between MacPRL and MicPRL.

Regulation of VEGF expression has been studied in different models (Table 7B). Estradiol, IL-6, and pituitary adenylate cyclase activating peptide (PACAP) have all been shown to increase VEGF expression, whereas dexamethasone (as in other cell types; Table 2A) inhibits VEGF. We have shown that hypoxia is an important stimulus to VEGF expression in cultured human pituitary adenoma cells (Fig. 6). Further studies are required to investigate whether this occurs via the HIF-1 signaling pathway.

View larger version (38K): [in this window] [in a new window]   FIG. 6. Graph showing VEGF concentrations in conditioned medium for primary pituitary tumor cell culture in normoxia (95% air) and hypoxia (0.1% oxygen). x-axis, Case represents each tumor studied; y-axis, VEGF (nanograms per milliliter) concentration in conditioned medium (Turner, H. E., unpublished observations).

4. LIF.
LIF has been detected in conditioned medium from bovine pituitary follicular cells in culture (222). Because LIF inhibited aortic endothelial but not adrenal capillary cell proliferation, it has been suggested that LIF may inhibit arteriogenesis in the pituitary gland, ensuring that the majority of the blood supply is capillary in origin, containing the regulatory hypophyseal factors (222). LIF has been shown to be present in normal adult pituitary tissue as well as human pituitary adenomas (289) and Rathke’s cleft cysts (290).

E. Genes and regulation of angiogenesis
PTTG was cloned from the rat pituitary cell line GH4 (285). Overexpression of rat PTTG in NIH-3T3 fibroblasts induced cellular transformation in vitro and in vivo in nude mice (285). Human PTTG is expressed in most pituitary adenomas at higher levels than in the normal gland, and human PTTG protein is demonstrable in adenoma cell cytoplasm (286). The exact role of PTTG in pituitary tumor development is as yet unclear. Recently, PTTG has been identified as a mammalian securin homolog and shown to inhibit chromatid separation, interfering with mitosis and potentially inducing genetic instability (291). PTTG expression and phosphorylation are related to mitosis, suggesting that PTTG may play a role in cell proliferation (292).

Experiments using the estrogen-induced rat prolactinoma model showed that estradiol also induced PTTG expression, followed within 24 h by increased FGF-2 and VEGF expression, associated with new pituitary blood vessel expression (281). Concordant expression of PTTG and FGF-2 was shown in human pituitary adenomas. Thus, PTTG overexpression may be an important mechanism of estrogen-induced tumorigenesis and angiogenesis. Administration of FGF-2 antibodies to conditioned medium derived from human PTTG-transfected 3T3 cells led to abrogation of angiogenesis in vitro and in vivo. The mechanism whereby PTTG is able to induce FGF-2 is currently unknown. FGF-2 has also been shown to induce cyclin D3 expression in rat pituitary (293). This may therefore provide a mechanism for an increase in cell proliferation associated with angiogenesis because cyclin D3 plays an important role in cell cycle control.

F. Matrix metalloproteinases
Tumor invasion of surrounding tissues is characteristic of more aggressive and often malignant tumor behavior. A previous small study demonstrated that three invasive pituitary adenomas showed high MMP-9 activity in contrast to four noninvasive tumors (294). More recently, an in vitro study of cultured pituitary tumors has shown secretion of another MMP type IV collagenase—MMP-2 from pituitary tumors (295). In addition, this study showed the presence of pro-MMP-9 in two thirds of conditioned medium from cultured tumors.

Assessment of MMP-2 expression using immunohistochemistry in a cohort of human pituitary tumors showed no relationship with pituitary tumor behavior (our unpublished observations). In contrast, however, MMP-9 expression was related to macroprolactinoma invasiveness and nonfunctioning tumor regrowth (296), suggesting that MMP-9 expression is related to aggressive tumor behavior. MMP-9 expression, as expected, was associated with increased angiogenesis, but the mechanism of MMP-9 regulation in pituitary tumors is unknown. Several potential upstream promoters (e.g., cAMP response element binding protein, somatostatin, cyclin D1, FGF-2), may activate MMP-9 expression (297, 298, 299, 300).

G. Therapeutic application of angiogenesis inhibitors
There are few descriptions of the therapeutic use of inhibitors of angiogenesis in endocrine tumors. There have been some preliminary data in the Fischer 344 rat estrogen-induced prolactinoma model, suggesting that a synthetic inhibitor of angiogenesis may have a beneficial therapeutic effect (301, 302). These studies both investigated the effects of the fumagillin analog TNP-470 and demonstrated a reduction in lactotroph proliferation and neovascularization. This is further evidence of the potential importance of angiogenesis in pituitary tumor behavior. Somatostatin analogs have been demonstrated in vitro to possess angioinhibitory activity (157, 158, 159, 160), although it is unknown whether this is clinically relevant in, for example, acromegaly where these analogs are frequently used to control excess GH secretion.

In contrast to other tumor types, pituitary tumors are less vascular than the normal pituitary gland. Whether this is due to endogenous inhibitors of angiogenesis controlling the angiogenic switch, the relatively low growth rate of these tumors, or an ingrowth of a vascular supply from the systemic circulation is not yet known. There is clearly a relationship between tumor behavior and MVD in some tumor types. In the future, it will be important to explore whether these differences can be used to identify tumors with a more aggressive prognosis or to use serum or urinary markers to monitor tumor progression and also assess the role of newly developed antiangiogenesis therapies in treatment.

	IV. Adrenal Tumors

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

 
Both the normal adrenal gland and adrenal tumors are vascular structures. There is a complex arrangement between the different zones of the cortex and medulla whereby different hormones are synthesized in different areas and may play a role in the metabolism of other hormones, for example the effect of glucocorticoids on catecholamine metabolism. Similar to the pituitary gland, incidental adrenal cortical tumors are commonly encountered, but malignant tumors are found more commonly in the adrenal than the pituitary gland, and the differentiation of benign and malignant can be difficult when simply observing a histological specimen. Adrenal medullary tumors are associated with various familial syndromes, e.g., multiple endocrine neoplasia (MEN) 2, neurofibromatosis type 1 (NF-1), and VHL syndrome. Differences in angiogenesis and the balance of angiogenic growth factors and inhibitors may play a role in determining the observed variations in tumor behavior. A better understanding of the underlying mechanisms may help with understanding and predicting tumor biology in the adrenal gland.

A. Microvascular density of tumors
No differences in vascular density between the normal adrenal cortex, adrenal adenomas, and carcinomas were observed using CD34 as the endothelial marker (303) (Table 8). However, MVD was related to tumor behavior in pheochromocytomas, showing that invasive tumors had a significantly higher number of blood vessels than noninvasive tumors (304). Although it is likely that more aggressive tumors do have higher levels of angiogenesis, there was also a difference in tumor size between the two groups, but the relationship between angiogenesis and size was not assessed.

Serum VEGF is elevated in patients with adrenal tumors undergoing surgery (307). One month after surgery, there was a significant reduction in serum VEGF levels in patients with both cortical cancers and benign adrenocortical adenomas. However, whether serum VEGF provides a marker of long-term disease control or recurrence is not known.

Cultured bovine adrenal cortex cells express the FGF-2 gene and release FGF-2, which stimulates proliferation of adrenal cortical cells (308, 309, 310). The presence of FGF-2 and type IV collagenase (an enzyme that is able to break down the extracellular matrix) has been demonstrated in pheochromocytomas (311), but there was no association between either factor with tumor prognosis. A comparison between FGF-2 expression in the normal adrenal gland and within pheochromocytomas (312) showed higher expression of FGF-2 in pheochromocytomas. Thus, although both VEGF and FGF-2 are present in adrenal tumors, there are no data linking either angiogenesis or the angiogenic growth factors with tumor behavior, malignancy, or prognosis.

C. Matrix metalloproteinases
ISH has shown the presence of gelatinase A (MMP-2) in stromal tissue of neoplastic adrenal tumors (313). MMP-2 was undetected from benign tissue, providing preliminary information to suggest perhaps that MMP-2 may play a role in malignant adrenal tumor behavior. Membrane type 1 MMP (MT1-MMP), which activates gelatinase A, was present in both stromal and neoplastic tissue. More data on these, other MMPs, and their regulation are required.

D. Genes and regulation of angiogenesis
1. Adrenomedullary tumors and VHL syndrome.
VHL is an inherited cancer syndrome caused by a germline mutation of the VHL tumor suppressor gene, followed by functional loss of the remaining wild-type allele. It is characterized by extensively vascularized tumors including renal cell carcinoma and hemangioblastoma. It has recently been demonstrated that renal carcinomas lacking wild-type VHL protein express mRNA for VEGF under normal as well as hypoxic conditions (314) (Fig. 7). Reintroduction of wild-type VHL inhibited production of VEGF mRNA under normoxic conditions (315). It was therefore likely that VHL protein regulates VEGF expression and that VHL inactivation leads to loss of VEGF suppression (316). The VHL/VEGF mechanism has recently been further elucidated by the demonstration that the VHL protein has a critical role in degrading HIF-1, thus blocking binding to the HREs of the hypoxia-responsive genes (317). VHL interacts with other cellular proteins, forming a complex with sequence and structural similarity to the SCF class of ubiquitin ligases (318). The VHL protein acts as an E3 ubiquitin ligase specific for HIF-subunits, and this leads directly to oxygen-dependent ubiquination and degradation of HIF in the proteasome (319). The angiogenic phenotype of VHL tumors may therefore be due to constitutive HIF-1 activity. The VHL gene also plays a role in regulation of PAI-1, with lower plasminogen-activator mRNA and protein levels and higher PAI-1 levels in renal cell carcinoma cells expressing the mutant VHL gene (320). This would lead to a reduction in plasmin-mediated proteolysis of the extracellular matrix and therefore slower tumor growth and later development of metastases. Unlike renal cell carcinoma in which the VHL gene is inactivated in 75% of cases, the majority of sporadic pheochromocytomas are not associated with mutations in the VHL gene (321). However, it is not known whether differences in angiogenesis or VEGF expression occur in sporadic and VHL-associated pheochromocytomas.

View larger version (18K): [in this window] [in a new window]   FIG. 7. Mechanism of proangiogenic effects of mutant VHL protein. SU5416 is a competitive inhibitor of ATP binding selective for VEGFR-2, preventing VEGF signaling.

2. NF-1.
Pheochromocytomas also occur in patients with the inherited syndrome NF-1. Another candidate for an association between a genetic abnormality and angiogenesis is the proangiogenic factor midkine, and aberrant expression of midkine has been shown in the skin of patients with NF-1, but not in normal controls (324). Midkine-containing culture medium leads to increased endothelial and neurofibroma-derived cell proliferation, suggesting that midkine may be associated with NF-1.

3. Adrenocortical tumors.
Genetic abnormalities found in adrenocortical tumors include overexpression of the IGF-II gene in malignant tumors, leading to a mitogenic effect via the IGF-I receptor (325, 326). In hepatocellular carcinoma, IGF-II is also highly expressed, and it has recently been shown that hypoxia is a major stimulus to IGF-II expression, leading to increased VEGF mRNA and protein expression (130). IGF-II also led to increased angiogenesis, as demonstrated on the chick CAM assay (327). Thus, a possible link between known genetic abnormalities in adrenocortical carcinomas and angiogenesis is overexpression of IGF-II leading to increased angiogenesis. This concept, however, is yet to be explored within adrenal tumors.

E. Therapeutic application of angiogenesis inhibitors
There are no data on the effects of inhibitors of angiogenesis in adrenal tumors. However, early studies have investigated the possibility of therapy for VHL. To prevent further progression of VHL, a preliminary study investigating the effect of blockade of VEGF signaling is in progress (328). This involves the use of a VEGF tyrosine kinase receptor inhibitor (SU 5416), and although early results suggest it is well tolerated, there is no published outcome information, and no patients with pheochromocytomas have been studied. An animal study, however, has investigated the effect of another antiangiogenic agent, linomide, on VHL paraganglioma growth in nude mice (329). Reduction in tumor size, tumor vascularization, and VEGF mRNA was observed. These are preliminary reports, but they demonstrate that antiangiogenic therapy may be a potential adjunct in patients with VHL and phaeochromocytoma.

Thus, although there has been progress on the link between angiogenesis, tumor phenotype, and genetic abnormalities in VHL, there are few data on MVD or angiogenic factors in nonfamilial adrenocortical or medullary tumors. It would be important if an assessment of, for example, MVD allowed differentiation of benign from malignant phaeochromocytoma or if noninvasive assessment of vascularization predicted true incidental tumor compared with a biologically important tumor.

	V. Thyroid Tumors

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

 
Angiogenesis plays an important role in goiter development with endothelial cell proliferation occurring before increased proliferation of the thyroid follicular cells (330). Conditioned medium derived from cultured rat and porcine thyroid follicular cells increases endothelial growth and migration, suggesting a paracrine mechanism for angiogenesis control in the thyroid by endogenous angiogenic factors (331). Similarly, increases in both serum VEGF and the intrathyroidal vascular area have been shown in patients with Graves’ disease and Hashimoto’s thyroiditis (332).

A. Microvascular density of tumors
Thyroid tumors are more vascular than the normal thyroid gland. Assessment of angiogenesis using F8 labeling and quantification of MVD at hot spots in 128 papillary thyroid cancers demonstrated a threefold increase in tumor vascularity as compared with normal thyroid tissue (333) (Table 9).

The finding of a higher rate of vascularization in microinvasive follicular carcinomas, particularly adjacent to or penetrating the capsule, is consistent with the hypothesis that vascularity may play a role in tumor spread in follicular thyroid tumors (335). This is important because follicular tumors tend to spread via the blood stream, whereas papillary thyroid tumor spread occurs via the lymphatic system.

B. Angiogenic factors
1. VEGF.
VEGF is present in epithelial cells of normal thyroid gland, goiter, Graves’ disease, thyroiditis, and thyroid tumors (Table 10). Increased VEGF is demonstrable in thyroid tumors when compared with normal gland or benign tumors, although interestingly, papillary microcarcinoma does not show increased VEGF expression when compared with normal thyroid gland (344).

VEGF expression appears to be related to aspects of thyroid tumor behavior (Table 11). Higher VEGF expression is present in metastatic thyroid cancer when compared with nonmetastatic disease (341). Lymph node metastases of thyroid tumors showed increased VEGF with respect to the primary tumor (344). An attempt at quantification of VEGF expression using the percentage of labeled thyrocytes and intensity of immunostaining in papillary thyroid cancer demonstrated higher VEGF expression in metastatic compared with nonmetastatic cancers (348). The authors suggest this technique as a method for distinguishing those thyroid tumors more likely to metastasize. Differences in VEGF expression alter tumorigenic potential in thyroid cancer cell lines (347). VEGF overexpression in poorly tumorigenic cells led to the development of well-vascularized tumors, whereas transfection of an antisense construct to VEGF into an anaplastic cell line led to smaller tumors and poor vascularization (347). Higher VEGF expression correlates with tumor size in adults (344) and children (349).

In both papillary and follicular thyroid cancer, increasing VEGF expression parallels increases in cell proliferation assessed using the Ki-67 labeling index, suggesting that areas of increased cell division increase VEGF secretion, allowing increased angiogenesis (341). This is in contrast to the observation in pituitary adenomas in which no relationship between cell proliferation and MVD (226) was found and also differs from findings in breast and colorectal cancer (86, 231). This may be related to differences in the respective metabolic requirements of the tissue.

Tumor expression of both VEGF-C and -D promotes lymphatic vessel formation and metastasis to lymph nodes in models of epithelial tumors in immunodeficient mice (45, 46). Expression of soluble VEGFR-3 in a transgenic mouse model led to regression of embryonic lymphatic vessels, suggesting a possible therapeutic approach to inhibit tumor lymphangiogenesis and tumor spread (47). There are some data regarding VEGF-C in thyroid tumors, which may be important because papillary tumors typically spread via the lymphatic system (Fig. 8). A comparison of VEGF-C expression using Northern blotting, ISH, and immunohistochemistry demonstrated increased expression in papillary tumors compared with follicular tumors (346). Tumors spreading via lymphatics were shown to express increased VEGF-C, whereas those that spread via the bloodstream showed a fall in TSP (an angioinhibitory factor) (344). VEGFR-3, the VEGF-C receptor, has also been demonstrated using immunohistochemistry in thyroid tumors and has been shown to be up-regulated in some papillary thyroid tumors and their lymph node metastases, consistent with its role in lymphatic proliferation (344).

View larger version (16K): [in this window] [in a new window]   FIG. 8. Proposed mechanism of angiogenesis and lymphangiogenesis in papillary and follicular thyroid cancer.

There are preliminary data linking Trk B receptor with angiogenesis and tumor progression in medullary thyroid tumors. The Trk family is comprised of receptor tyrosine kinases (like RET) that bind neurotrophins and promote survival and growth of neural crest-derived cells. In medullary thyroid cancer, reduction in neurotrophin receptor TrkB expression and increase in TrkC are found in the later stages of tumor progression (350). In a cell culture model, TrkB expression led to reduced VEGF concentrations and reduced tumorigenicity, suggesting that TrkB may inhibit medullary thyroid carcinoma angiogenesis and tumor growth, with reduced expression associated with tumor progression altering the balance of malignancy toward a more angiogenic and potentially metastatic phenotype.

2. Other angiogenic factors.
Another proangiogenic factor, FGF-2, and its receptor, FGF-R1, are expressed as assessed by immunohistochemistry in follicular cells from papillary, follicular, and anaplastic thyroid carcinomas, suggesting a paracrine mechanism of angiogenesis and cell proliferation (351, 352). This had previously been suspected after studies in the rat FRTL-5 thyroid cell line, which showed that both FGF-2 and a high-affinity receptor (flg) localized and were synthesized in follicular cells (353). Additionally, exogenous and endogenous FGF-2 was mitogenic for follicular cells. Increased extracellular FGF-2 has been shown in Graves’ disease and papillary thyroid cancer, as compared with normal thyroid tissue (354). Follicular cell FGF-2 and TGF-ß1 immunoreactivity increase during increased angiogenesis associated with goiter progression in a rat model, whereas expression of the angioinhibitory factor TSP1 fell (355). Others demonstrated increased number and intensity of follicular cells immunostaining for FGF-1 and FGF-2 in multinodular goiter, further suggesting that these growth factors are important in the development of thyroid hyperplasia (356).

Although FGF-2 has direct angiogenic effects in other tissues and is clearly increased in thyroid inflammation, goiter, and carcinoma, all of which have been associated with increased angiogenesis, there are no published studies demonstrating a direct or indirect role of FGF-2 on thyroid angiogenesis.

Angiopoietin 2 has been demonstrated in thyroid tumors, with a marked increase in mRNA correlated with tumor size (344). Interestingly, this study showed no increase in Ang-1. Up-regulation of Tie2/Tek receptor mRNA has been shown in some of the papillary thyroid cancers and in the majority of lymph node metastases (344). This study also showed a reduction in the angioinhibitory factor TSP in aggressive thyroid tumors. Although no differences were noted between benign adenomas and papillary microcarcinoma, down-regulation of TSP mRNA in papillary thyroid tumors was particularly associated with lymph node metastases. Follicular carcinomas showed further reduction in TSP expression, as did medullary thyroid tumors, with further down-regulation demonstrable in their metastases.

HGF is the ligand for the tyrosine kinase receptor product of the c-met protooncogene and may play a role in papillary thyroid tumor angiogenesis and, in particular, in vascular invasion. HGF is increased with thyroid cancer invasiveness in vitro using a matrigel-coated nucleopore filter (357). In human keratinocytes, HGF also increases VEGF expression and up-regulates VEGFR-1 (358). Met mRNA and protein overexpression has been demonstrated in thyroid cancer cell lines (359). These studies showed that the cell lines responded to HGF, leading to increased invasiveness. Papillary carcinoma, but not anaplastic or follicular thyroid cancer or normal thyroid gland, overexpresses both HGF and c-met (360, 361, 362, 363). Loss of heterozygosity (LOH) for HGF and c-met occurs in follicular and anaplastic cancer, but not papillary cancer at the loci for these proteins—7q21 and 7q31, respectively (362). It is also of potential diagnostic use in differentiation of follicular from papillary phenotype. Although some work in human thyroid tissue has not shown a correlation between c-met expression and papillary thyroid cancer behavior (364), others have shown that the extent of MET expression in papillary thyroid cancer predicts both vascular invasion and the likelihood of distant metastases (360). Activation of ras and ret oncogenes, both known to play a role in thyroid tumorigenesis, leads to overexpression of c-met, which in turn increases thyroid epithelial cell sensitivity to paracrine HGF (365). This may, in part, explain the mechanism of proliferative advantage caused by these oncogenes.

Thus, from the data available, the balance of angiogenesis in the thyroid appears to involve increases in VEGF and its receptors in addition to angiopoietin and Tie2/Tek, allowing increased tumor size and possibly metastasis. Other growth factors including FGF-2 may play a permissive role in increased angiogenesis during tumor growth and progression. Reduction in TSP may then allow distant metastasis to occur, and VEGF-C and its receptor may play a role in lymphatic spread in papillary tumors. Expression of HGF and its receptor demonstrate a potential link between genetic abnormalities in tumors and differences in vascular invasion and tumor behavior.

C. Matrix metalloproteinases
The experimental data on the MMP family in thyroid tumors suggest that the type IV collagenase, MMP-2, may be the most important member of the family in determining thyroid tumor invasiveness (Table 12). Although the MMPs are expressed mainly in thyroid carcinomas, they may also be expressed in nonneoplastic tissue, most consistently in areas of thyroid inflammation.

Immunohistochemistry demonstrated the presence of MMP-2 in papillary and follicular thyroid carcinomas as well as lower expression in inflammatory nonneoplastic thyroid tissue (369). An investigation using sandwich enzyme immunoassays of MMP expression in human invasive papillary thyroid carcinoma demonstrated that only MMP-2 production is enhanced when compared with adenomas and normal thyroid gland (370). Activation of MMP-2 from pro-MMP-2 was investigated using gelatin zymography and shown to be elevated in tumors associated with lymph node metastasis (370). Increased expression of the MMP-2 activator, MT1-MMP, in carcinoma tissue and correlation with MMP-2 activity and distant metastasis were demonstrated using Northern blot. This suggests that activation of pro-MMP-2 by MT1-MMP may play an important role in determining papillary thyroid carcinoma metastasis. MMP-9, the other type IV collagenase able to degrade basement membrane in particular, does not appear to be important for thyroid cancer invasion (370, 371).

In addition to the MMP system, the plasmin activation system proteolytic enzyme may lead to extracellular matrix degradation. An investigation of follicular thyroid carcinoma cell lines with metastases (FTC-236 and FTC-238) and without metastases (FTC-133) demonstrated that both the plasmin activation and MMP system were involved in matrix degradation, because inhibitors of both systems led to reduction in invasion (372). The plasmin activation system is also important in generation of angiogenesis inhibitors, e.g., angiostatin (144). There are no data on the role of angiostatin in the thyroid.

D. Therapeutic application of angiogenesis inhibitors
The effects of therapy with carbimazole, propylthiouracil, or radioiodine on angiogenesis have not been studied; however, it has been known for many years that potassium iodide reduces thyroid gland vascularity before surgery, although the mechanism for this observation is unknown.

There is little information on the effect of therapy with antiangiogenesis agents. However, administration of TNP-470, a synthetic fumagillin analog, inhibited anaplastic thyroid cancer xenograft growth in nude mice with significant vasculature reduction (373). This suggests a possible future therapeutic strategy for anaplastic thyroid carcinoma. An investigation of the antineoplastic effects of phenylacetate has shown inhibition of the growth of follicular thyroid cancer cell lines in vitro (374). Phenylacetate inhibited VEGF secretion from the thyroid cancer cell lines, suggesting a potential therapeutic strategy in patients with differentiated thyroid cancer.

E. Genes and regulation of angiogenesis
Mutation of the tumor suppressor gene p53 is common in anaplastic thyroid cancer and, as shown in other tumor types, this leads to down-regulation of the angiogenesis inhibitor TSP1 with tumor dormancy and suppression of neovascularization (375, 376).

The data summarized above demonstrate that angiogenesis is important in the pathogenesis of thyroid tumors. Thyroid tumors (in contrast to the pituitary) are more vascular than nontumorous thyroid tissue, and VEGF expression is higher. Although an inconsistent relationship is reported between vascular density and tumor behavior, there is a clear correlation between increasing VEGF expression and more aggressive tumor behavior. The association between the lymphatic angiogenic factors and papillary tumor metastasis and reduction in TSP-C and follicular tumor vascular spread may explain, in part, commonly observed differences in tumor behavior. The relatively common finding of an incidentally detected thyroid cancer (microcarcinoma), which does not progress to a clinically relevant cancer, may be due to absent angiogenesis. This is likely because the balance of angiogenesis favors inhibition of new vessel formation, which maintains the characteristic dormancy of the microtumor. A soluble VEGFR-3 or neutralizing antibodies to VEGF-C, VEGF-D, or VEGFR-3 may offer a potential low-toxicity strategy to the management for follicular thyroid cancer, and MMP-2 may in the future serve as a marker and therapeutic target for invasive or metastatic thyroid carcinoma.

	VI. Parathyroid Tumors

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

 
Parathyroid tissue is unusual in that autotransplanted gland or hyperplasia induces neovascularization in vivo. Animal studies have suggested that parathyroid adenoma tissue stimulates angiogenesis in the rabbit iris model in vivo (377) and also in vitro (378). Coculture of canine parathyroid gland led to a significant increase in microvessel density, which was not seen with injections of PTH or calcium alone (378). The control and mechanism of the angiogenic switch in parathyroid tissue is not known.

Primary hyperparathyroidism arises due to the presence of adenomas in 80–85% cases, carcinoma in 2–3%, and hyperplasia in the remainder of cases. The majority of cases are sporadic, but familial cases are associated with MEN 1 and MEN 2A, familial isolated hyperparathyroidism, and the hyperparathyroidism jaw tumor syndrome. Parathyroid tumors may also arise in chronic renal failure. Because of multigland involvement, it has been assumed that parathyroid tumors in chronic renal failure and parathyroid hyperplasia involve polyclonal cellular proliferations. X-chromosome inactivation analysis showed that seven of 11 (64%) patients with uraemic refractory hyperparathyroidism harbored at least one monoclonal parathyroid tumor and that monoclonality was demonstrable in six of 16 (38%) with primary parathyroid hyperplasia (379). Another study has confirmed these findings in uraemic hyperparathyroidism, demonstrating a monoclonal pattern in 58% of hyperplastic nodules (380). These studies suggest that monoclonal parathyroid neoplasms are common in uraemic hyperparathyroidism and parathyroid hyperplasia.

A. Microvascular density of tumors
The endothelial component of parathyroid glands was investigated using ultrastructural morphometry in six patients with MEN 1 and compared with six patients with uraemic hyperplastic glands (381). The volume of capillaries and the number of capillaries per unit area were significantly higher in patients with MEN 1 compared with uraemic glands, suggesting increased vascular density in parathyroid glands removed from patients with MEN 1 compared with uraemic glands. It has previously been proposed that this may be related to elevated circulating FGF-2 found in the sera of these patients (381).

B. Angiogenic factors
1. VEGF.
There are no data available on the presence of VEGF in parathyroid tumors. An endothelial cell line has been established from human parathyroid tissue surgically removed from a patient with MEN 1, known as HPE (382). FGF-2, VEGF, IGF-I, and ascorbic acid stimulate cell proliferation, whereas PTH was inert. TGF-ß and heparin were inhibitory factors. Using PCR and restriction fragment length polymorphism, allelic loss was not evident at the MEN 1 locus on chromosome 11q12–13. It would be interesting to see further results regarding this potentially interesting tool.

2. FGF-2.
RT-PCR studies of FGF and receptors in parathyroid disease [normal, renal hyperparathyroidism (hyperplastic) and PT adenomas], demonstrated that FGF-R1 was present in all glands, and FGF-R2 was present in most glands (383). FGF-1 and -2 were expressed in all samples with no correlation with disease type, whereas elevated FGF-3 levels were found in some diseased glands. Of potential importance, the FGF-3 gene (and FGF-2) is present on 11q13.3. There are no data on the potential role of FGF-4 or the newly described PTTG expression in parathyroid tumors.

A study comparing FGF-2 immunohistochemistry in hyperplastic parathyroid tissue derived from patients with MEN 1 and those without MEN 1 demonstrated the presence of FGF-2 in both groups, but more commonly in patients with MEN 1 (384). Circulating FGF-2-like substance has been demonstrated in patients with MEN 1 (279), and circulating FGF-2 has been shown to increase clonal bovine endothelial cell proliferation (385).

3. IGF-I.
Parathyroid cells from adenomas and hyperplasia bind IGF-I, and cultured human parathyroid cells respond to IGF-I with increased IGF-I synthesis (386). IGF-I and IGF-II stimulate bovine parathyroid cell growth in vitro (387). There are no data, however, regarding a link between IGF-I and parathyroid vascularization or control of the angiogenic switch.

4. TGF-.
Cytoplasmic expression of TGF- and its receptor, the EGF receptor, was demonstrated in parathyroid adenomas and surrounding normal tissue (388). Others have demonstrated the presence of TGF- mRNA and protein in parathyroid adenomas and hyperplasia, but not in normal parathyroid tissue (389). This study also demonstrated the presence of EGF-R protein and mRNA in parathyroid adenomas, hyperplasia, and normal tissue (389). EGF protein and mRNA were virtually undetectable. This may represent an important autocrine mechanism in parathyroid pathophysiology.

TGF- stimulates proliferation of bovine parathyroid cells in culture and enhances proliferation associated with IGF-I or -II alone (387). EGF did not stimulate growth. The same group demonstrated the presence of EGF-R mRNA in parathyroid cancer, parathyroid hyperplasia, and less commonly parathyroid adenomas, but no immunoreactive EGF-R protein was detected due to either low receptor numbers or possible failure of transcription (390). Whether TGF- is linked to control of the angiogenic switch in the parathyroid gland is not known.

C. Matrix metalloproteinases
Although PTH regulates MMP-2 and MMP-9 (Table 2) in cultured osteoblasts and chondrocytes, thereby playing a potential role in matrix degradation allowing bone cell migration, there is no information on the role of MMPs in parathyroid tumor behavior.

D. Genes and regulation of angiogenesis
Loci associated with LOH in parathyroid tumors include 11q13 in both MEN 1 and also approximately one third of sporadic tumors (391, 392, 393, 394). This locus (11q13) is also the site of the cyclin D1 gene (395), and rearrangements at this locus have been associated with D1 overexpression (396). Of potential relevance is the fact that the VEGF gene is also found at 11q13. It would be important to explore whether cyclin D1 overexpressing cells express more VEGF than quiescent cells.

Another site of LOH in 27% of sporadic parathyroid tumors is 1p35–36 (397). This locus is the position of p73, a new member of the p53 family, which has been mapped to 1p36. p73 Down-regulated VEGF gene expression by repression of the VEGF promoter and so reduced transcription (398). Two loci associated with vascular malformations (1p21–22 and 9p21) are also found to be associated with LOH in sporadic parathyroid tumors. The gene at 9p21, for example, causes ligand-independent activation of the endothelial cell-specific receptor tyrosine kinase Tie-2 (399). The relationship between these genetic changes and the angiogenic phenotype of parathyroid tumors has thus far not been studied. Clearly, these are huge loci with many genes, and the possible relationship between LOH and potential genetic changes linked with angiogenesis is speculative at present.

It is clear that when parathyroid tissue is autotransplanted, the angiogenic switch is activated. This process, however, appears to be carefully controlled because the majority of parathyroid tumors are benign and do not metastasize. The components of this delicately balanced mechanism are not known. PTH itself regulates bone VEGF and MMP expression. Whether there is a direct paracrine mechanism within the parathyroid gland itself is not clear. There are several possible genotype-angiogenic phenotype clues in parathyroid tumor pathogenesis that may further elucidate these mechanisms.

	VII. Carcinoid Tumors

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

 
MVD has been investigated in a series (n = 72) of lung carcinoid tumors using quantification of the vascular density of CD34-labeled endothelium at hot spots (400). This showed no relationship between angiogenesis assessed in this way and tumor metastasis, size, or histological type (atypical or typical). Immunohistochemistry for VEGF showed strong immunopositivity in midgut carcinoid tumor cells, whereas the protein is undetectable in stromal cells and endothelial cells (401). This may explain why conditioned medium from a human pancreatic carcinoid cell line led to stimulatory effects on both endothelial cells and fibroblasts (402). Tumor production of TGF- or -ß may also play a role in vascular proliferation in stromal cells adjacent to the tumor and the subsequent fibrosis characteristic of carcinoid syndrome due to matrix production (403, 404).

	VIII. Gastrointestinal Neuroendocrine Tumors

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

 
VEGF is expressed in normal pancreatic islets, with up-regulation occurring during tumor development in the transgenic mouse model of islet cell neoplasia (30). VEGFR-1 and VEGFR-2 are expressed in normal islets and in tumors but are not up-regulated during tumorigenesis. VEGF has been shown to stimulate islet cell proliferation and enhance insulin content (405, 406). VEGF also colocalizes with insulin in pancreatic islet cells (407). Northern blot analysis of mRNA rodent insulinoma cell lines demonstrates VEGF mRNA and VEGF protein present in conditioned medium derived from a cell line using Western blot (407). Thus, it appears that VEGF may play an important paracrine role during both normal and neoplastic pancreatic islet cell proliferation and endocrine function.

Immunoreactive VEGF expression in 16 of 20 surgically removed neuroendocrine pancreatic tumors had no relationship between VEGF immunostaining and tumor stage (401). Tumor VEGF was located within neuroendocrine tumor cells. Neutralizing antibodies to VEGF reduced liver metastasis and tumor growth in a human neuroendocrine neoplasm transplanted to mice (408). These are preliminary data in an animal model, but they suggest a future therapeutic strategy.

Whether the angiogenic phenotype of carcinoids or other gastrointestinal neuroendocrine tumors allows for prognostic or therapeutic decision making is as yet unclear. The relationship between VEGF and other preangiogenic growth factors with endogenous and therapeutically administered substances known to inhibit angiogenesis such as octreotide and its analogs is not known. Further work is required on the potential of antiangiogenic strategies such as VEGF antibodies or MMP inhibitors in these tumors, which are more commonly malignant and less commonly cured by surgery alone.

	IX. Conclusions

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

 
The relationship between angiogenesis and endocrine tumor behavior is yet to be fully explored. Although there are common features, tumors arising in different endocrine glands differ significantly in behavior and also in aspects of angiogenesis thus far studied. For example, pituitary tumors are less vascular than normal gland, whereas in the thyroid, hyperplasia and goiter as well as tumors are more vascular than normal thyroid. Malignant tumors are more common in thyroid and adrenal but very rare in the pituitary and parathyroid. Tumors are associated with genetic syndromes in the parathyroid and adrenal medulla, whereas they are more rarely associated with pituitary and thyroid tumors. With relevance to an understanding of angiogenesis, endocrine glands differ from nonendocrine tissue in their typically very vascular structures, with fenestrated endothelium and dependence for normal function in tight regulatory feedback loops requiring an excellent blood supply. Microtumors are commonly found in endocrine glands in which the vast majority will not increase in size. An understanding of the control of these tumors and the role of potential endogenous inhibitors of angiogenesis, e.g., 16-kDa PRL and somatostatin, will help with understanding the angiogenic balance. Although it is crucial that normal endocrine glands are vascular and have fenestrated vessels to allow easy hormone transfer across the endothelium, it is important that this is carefully regulated. The possible explanation of lack of activation of the angiogenic switch for common incidental tumors in pituitary, thyroid, and adrenal would be instructive in understanding the concept of tumor dormancy and would have potential implications for understanding tumor biology as well as possible therapy. The mechanism of the balance of angiogenesis and interaction with the extracellular matrix and MMPs may further advance the understanding of tumor invasiveness and patterns of invasion (vascular, bony, or lymphatic). The definition of genetic steps determining different angiogenic phenotypes and therefore tumor progression might increase our understanding of neoplastic progression and also allow measurement of markers of aggressive tumor behavior, initiation of appropriate therapy, and monitoring of tumor behavior.

	Footnotes

 
Abbreviations: CAM, Chorioallantoic membrane; EGF, epidermal growth factor; ER, estrogen receptor; F8, factor eight-related antigen; FGF, fibroblast growth factor; FGFR, FGF receptor; FSC, folliculostellate cells; HGF, hepatocyte growth factor; HIF, hypoxia inducible factor; HRE, hypoxia response element; HUVEC, human umbilical vein endothelial cell(s); IGFBP, IGF binding protein; ISH, in situ hybridization; LIF, leukemia inhibitory factor; LOH, loss of heterozygosity; MEN, multiple endocrine neoplasia; MMP, matrix metalloproteinase; MT1-MMP, membrane type 1 MMP; MVD, microvascular density; NF-1, neurofibromatosis type 1; NFA, nonfunctioning adenoma or tumor(s); PACAP, pituitary adenylate cyclase activating peptide; PAI-1, plasminogen activator inhibitor 1; PRL, prolactin; PTTG, pituitary tumor-transforming gene; TIMP, tissue inhibitors of metalloproteinase; TSP, thrombospondin; UEA1, ulex europaeus agglutinin 1; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; VHL, Von Hippel Lindau.

	References

Top Abstract I. Introduction II. Mechanism of Angiogenesis III. Pituitary Tumors IV. Adrenal Tumors V. Thyroid Tumors VI. Parathyroid Tumors VII. Carcinoid Tumors VIII. Gastrointestinal... IX. Conclusions References

 

1. Risau W 1997 Mechanisms of angiogenesis. Nature 386:671–674[CrossRef][Medline]
2. Reynolds LP, Killilea SD, Redmer DA 1992 Angiogenesis in the female reproductive system. FASEB J 6:886–892[Abstract]
3. Folkman J 1995 Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757–1763[Free Full Text]
4. O’Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, Schwartz SM 1994 Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 145:883–894[Abstract]
5. Colville Nash PR, Scott DL 1992 Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 51:919–925[Abstract/Free Full Text]
6. Sharp PS 1995 The role of growth factors in the development of diabetic retinopathy. Metabolism 44:72–75[CrossRef][Medline]
7. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ 1994 Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144:820–828[Abstract]
8. Folkman J 1990 What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82:4–6[Free Full Text]
9. Gimbrone Jr MA, Leapman S, Cotran RS, Folkman J 1972 Tumour dormancy in vivo by prevention of neovascularisation. J Exp Med 73:461–473
10. Gimbrone Jr MA, Leapman S, Cotran RS, Folkman J 1973 Tumor angiogenesis: iris neovascularization at a distance from intraocular tumors. J Natl Cancer Inst 50:219–228
11. Folkman J 1972 Anti-angiogenesis: a new concept for therapy of solid tumours. Ann Surg 175:409–416[Medline]
12. Weidner N, Semple JP, Welch WR, Folkman J 1991 Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324:1–8[Abstract]
13. Weidner N, Carrol PR, Flax J, Blumenfeld W, Folkman J 1993 Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401–409[Abstract]
14. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G 1992 Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 84:1875–1887[Abstract/Free Full Text]
15. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL 1992 Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120–1124[CrossRef][Medline]
16. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Sawada T, Yamashita Y, Onoda N, Kato Y, Nitta A, Arimoto Y 1995 Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 13:477–481[Abstract/Free Full Text]
17. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW 1995 Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87:1603–1612[Abstract/Free Full Text]
18. Simionescu N, Simionescu M 1988 In: Weiss L, ed. Cell and tissue biology. Baltimore: Urban and Schwarzemberg; 355–398
19. Palade GE, Simoniescu M, Simoniescu N 1979 Structural aspects of the permeability of the microvascular endothelium. Acta Physiol Scand 463:11–32
20. Brem SS, Gullino PM, Medina D 1978 Angiogenesis as a marker of pre-neoplastic lesions of the human breast. Cancer 41:239–244[CrossRef][Medline]
21. Dobbs SP, Hewett PW, Johnson IR, Carmichael J, Murray JC 1997 Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br J Cancer 76:1410–1415[Medline]
22. Smith-McCune KK, Weidner N 1994 Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54:800–804[Abstract/Free Full Text]
23. Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP 1999 Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumor progression. Int J Cancer 81:845–850[CrossRef][Medline]
24. Jensen HM, Chen I, DeVault MR, Lewis AE 1982 Angiogenesis induced by ‘normal’ human breast tissue: a probable marker for precancer. Science 218:293–295[Abstract/Free Full Text]
25. Folkman J, Watson K, Ingber D, Hanahan D 1989 Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58–61[CrossRef][Medline]
26. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D 1999 Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808–812[Abstract/Free Full Text]
27. Bicknell R 1997 Mechanistic insights into tumor angiogenesis. In: Bicknell ER, Lewis CE, Ferrara N, eds. Tumor angiogenesis. Oxford, UK: Oxford University Press; 19–28
28. Risau W, Flamme I 1995 Vasculogenesis. Ann Rec Cell Dev Biol 1:73–91
29. Hanahan D, Folkman J 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364[CrossRef][Medline]
30. Christofori G, Naik P, Hanahan D 1995 Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 9:1760–1770[Abstract/Free Full Text]
31. Relf M, LeJeune S, Scott AE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL 1997 Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor ß-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963–973[Abstract/Free Full Text]
32. Ferrara N 1996 Vascular endothelial growth factor. Eur J Cancer 32A:2413–2422
33. Powers CJ, McLeskey SW, Wellstein A 2000 Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165–197[Abstract]
34. Folkman J, Shing Y 1992 Angiogenesis. J Biol Chem 267:10931–10934[Free Full Text]
35. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR 1993 Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143:1255–1262[Abstract]
36. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF 1993 Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53:4727–4735[Abstract/Free Full Text]
37. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ 1995 Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86–91[CrossRef][Medline]
38. Ferrara N, Davis-Smyth T 1997 The biology of vascular endothelial growth factor. Endocr Rev 18:4–25[Abstract/Free Full Text]
39. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B 1998 Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715–725[CrossRef][Medline]
40. Plate KH, Breier G, Weich HA, Risau W 1992 Vascular endothelial growth factor is a potential tumor angiogenesis factor in vivo. Nature 359:845–847[CrossRef][Medline]
41. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O’Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL, Gatter KC 1998 Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4:3017–3024[Abstract]
42. Olofsson B, Pajusola K, Kaipaineen A, Von Euler G, Joukov V, Saksela O, Orpana A, Petterson R, Alitalo K, Eriksson U 1996 Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93:2576–2581[Abstract/Free Full Text]
43. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U 1998 Vascular endothelial growth factor B (VEGF B) binds to VEGF receptor 1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 95:11709–11714[Abstract/Free Full Text]
44. Plate KH 2001 From angiogenesis to lymphangiogenesis. Nat Med 2:151–152
45. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG 2001 VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7:186–191[CrossRef][Medline]
46. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M 2001 Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192–198[CrossRef][Medline]
47. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, Herttuala S, Alitalo K 2001 Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor 3. Nat Med 7:199–205[CrossRef][Medline]
48. Jussila L, Alitalo K 2002 Vascular growth factors and lymphangiogenesis. Physiol Rev 82:673–700[Abstract/Free Full Text]
49. Shibuya M 2001 Structure and function of VEGF/VEGF receptor system involved in angiogenesis. Cell Struct Funct 26:25–35[CrossRef][Medline]
50. Schlessinger J 2000 Cell signalling by receptor tyrosine kinases. Cell 103:211–225[CrossRef][Medline]
51. Fong GH, Rossant J, Gertsenstein M, Breitman ML 1995 Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66–70[CrossRef][Medline]
52. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC 1995 Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62–66[CrossRef][Medline]
53. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K 1998 Cardiovascular failure in mouse embryos deficient in VEGF R3. Science 282:946–949[Abstract/Free Full Text]
54. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841–844[CrossRef][Medline]
55. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N 1995 Regulation by vascular endothelial growth factor of human colon cancer tumorogenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789–1797
56. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599[Abstract/Free Full Text]
57. Melnyk O, Zimmerman M, Kim KJ, Shuman M 1999 Neutralising anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 161:960–963[CrossRef][Medline]
58. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K 1995 Expression of the Fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92:3566–3570[Abstract/Free Full Text]
59. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K 1996 A novel vascular endothelial growth factor, VEGF C is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290–298[Medline]
60. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA 1998 Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (flk-1) and VEGF receptor 3 (Flt-4). Proc Natl Acad Sci USA 95:548–553[Abstract/Free Full Text]
61. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE 1995 Suppression of retinal neovascularisation in vivo by inhibition of vascular endothelial growth factor using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92:10457–10461[Abstract/Free Full Text]
62. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH 1998 Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4:336–340[CrossRef][Medline]
63. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG 1998 Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9:49–58[Abstract]
64. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A 1994 Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576–579[CrossRef][Medline]
65. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ulrich A, Strawn LM 1996 Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56:1615–1620[Abstract/Free Full Text]
66. Ferrara N 2000 Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55:15–36
67. Semenza GL 2001 HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13:167–171[CrossRef][Medline]
68. Shweiki D, Itin A, Soffer D, Keshet E 1992 Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845[CrossRef][Medline]
69. Stein I, Neeman M, Shweiki D, Itin A, Keshet E 1995 Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 15:5363–5368[Abstract/Free Full Text]
70. Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, Leung S, Roe R, Wiener C, Yu A 1997 Structural and functional analysis of hypoxia inducible factor 1. Kidney Int 51:553–555[Medline]
71. Maxwell PH 2002 Oxygen homeostasis and cancer: insights from a rare disease. Clin Med 2:356–362[Medline]
72. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ 1997 Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94:8104–8109[Abstract/Free Full Text]
73. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S 1995 Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 270:12607–12613[Abstract/Free Full Text]
74. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K 1994 Vascular endothelial growth factor is induced in response to transforming growth factor-ß in fibroblastic and epithelial cells. J Biol Chem 269:6271–6274[Abstract/Free Full Text]
75. Li J, Perrella MA, Tsai JC, Yet SF, Hsieh CM, Yoshizumi M, Patterson C, Endege WO, Zhou F, Lee ME 1995 Induction of vascular endothelial growth factor gene expression by interleukin-1 ß in rat aortic smooth muscle cells. J Biol Chem 270:308–312[Abstract/Free Full Text]
76. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM 1998 Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58:4008–4014[Abstract/Free Full Text]
77. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB 1996 Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 271:29483–29488[Abstract/Free Full Text]
78. Mukhopadhyay D, Tsiokas L, Sukhatme VP 1998 High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation. Gene Expr 7:53–60[Medline]
79. Jones N, Iljin K, Dumont DJ, Alitalo K 2001 Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2:257–267[CrossRef][Medline]
80. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG 1998 Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 78:1385–1394[Medline]
81. Dunk C, Shams M, Nijjar S, Rhaman M, Qiu Y, Bussolati B, Ahmed A 2000 Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. Am J Pathol 156:2185–2199[Abstract/Free Full Text]
82. Visconti RP, Richardson CD, Sato TN 2002 Orchestration and arteriovenous contribution by angiopoietins and vascular endothelial growth factor. Proc Natl Acad Sci USA 99:8219–8224[Abstract/Free Full Text]
83. Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A 1998 Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139:451–456[Abstract/Free Full Text]
84. Folkman J 1998 Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 139:441–442[Free Full Text]
85. Toi M, Inada K, Suzuki H, Tominaga T 1995 Tumor angiogenesis in breast cancer: its association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36:193–204[CrossRef][Medline]
86. Fox SB, Gatter KC, Bicknell R, Going JJ, Stanton P, Cooke TG, Harris AL 1993 Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 53:4161–4163[Abstract/Free Full Text]
87. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY 1996 Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484
88. Holthofer H, Virtanen I, Kariniemi AL, Hormia M, Linder E, Miettinen A 1982 Ulex europaeus 1 lectin as a marker for vascular endothelium in human tissues. Lab Invest 47:60–66[Medline]
89. Schlingeman RO, Rietveld FJR, de Waal RMW, Bradley NJ, Skene AI, Davies AJS, Greaves MF, Denekamp J, Ruiter DJ 1990 Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 62:690–696[Medline]
90. Mukai K, Rosai J, Burgdorf WH 1980 Localization of factor VIII-related antigen in vascular endothelial cells using an immunoperoxidase method. Am J Surg Pathol 4:273–276[Medline]
91. Witt M, Klessen C 1987 Galactose and fucose binding sites in anterior pituitary cells of the rat: detection by means of biotinylated lectins. Folia Histochemica et Cytobiologica 25:115–118
92. Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E 1998 Expression of Tie2/Tek in breast tumor vasculature provides a new marker for evaluation of tumor angiogenesis. Br J Cancer 77:51–56[Medline]
93. Salven P, Joensuu H, Heikkila P, Matikainen MT, Wasenius VM, Alanko A, Alitalo K 1996 Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis. Br J Cancer 74:69–72[Medline]
94. Wang JM, Kumar S, Pye D, van-Agthoven AJ, Krupinski J, Hunter RD 1993 A monoclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues. Int J Cancer 54:363–370[Medline]
95. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE 1995 Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1:1623–1634[Abstract]
96. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC 1998 Detection of tumor angiogenesis in vivo by Vß3-targeted magnetic resonance imaging. Nat Med 4:623–626[CrossRef][Medline]
97. Kakolyris S, Giatromanolaki A, Koukourakis M, Leigh IM, Georgoulina V, Kanavaros P, Sivridis E, Gatter KC, Harris AL 1999 Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. Cancer Res 59:5602–5607[Abstract/Free Full Text]
98. Kakolyris S, Fox SB, Koukourakis M, Giatromanolaki A, Brown N, Lee RD, Taylor M, Leigh IM, Gatter KC, Harris AL 2000 Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH 39. Br J Cancer 82:844–851[CrossRef][Medline]
99. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL 1995 Quantification and prognostic value of breast cancer angiogenesis: Chalkley count and computer image analysis. J Pathol 177:275–283[CrossRef][Medline]
100. Barbareschi M, Weidner N, Gasparini G, Morelli L, Forti S, Eccher C, Fina P, Caffo O, Leonardi E, Mauri F, Bevilacqua P, Palma PD 1995 Microvessel density quantification in breast carcinomas. Appl Immunohistochem 3:75–84
101. Banerjee SK, Campbell DR, Weston AP, Banerjee DK 1997 Biphasic estrogen response on bovine adrenal medulla capillary endothelial cell adhesion, proliferation and tube formation. Mol Cell Biochem 177:97–105[CrossRef][Medline]
102. Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, Harkonen PL 1999 Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 149:29–40[CrossRef][Medline]
103. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM 2000 Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60:3183–3190[Abstract/Free Full Text]
104. Ali SH, O’Donnell AL, Mohamed S, Mousa S, Dandona P 1999 Stable over-expression of estrogen receptor- in ECV304 cells inhibits proliferation and levels of secreted endothelin-1 and vascular endothelial growth factor. Mol Cell Endocrinol 152:1–9[CrossRef][Medline]
105. Agrawal R, Prelevic G, Conway GS, Payne NN, Ginsburg J, Jacobs HS 2000 Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. Fertil Steril 73:56–60[CrossRef][Medline]
106. Iruela-Arispe ML, Porter P, Bornstein P, Sage EH 1996 Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. J Clin Invest 97:403–412[Medline]
107. Hyder SM, Murthy L, Stancel GM 1998 Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 58:392–395[Abstract/Free Full Text]
108. Artini PG, Monti M, Fasciani A, Tartaglia ML, D’Ambrogio G, Genazzani AR 1998 Correlation between the amount of follicle-stimulating hormone administered and plasma and follicular fluid vascular endothelial growth factor concentrations in women undergoing in vitro fertilization. Gynecol Endocrinol 12:243–247[Medline]
109. Anasti JN, Kalantaridou SN, Kimzey LM, George M, Nelson LM 1998 Human follicle fluid vascular endothelial growth factor concentrations are correlated with luteinization in spontaneously developing follicles. Hum Reprod 13:1144–1147[Abstract/Free Full Text]
110. Schiffenbauer YS, Abramovitch R, Meir G, Nevo N, Holzinger M, Itin A, Keshet E, Neeman M 1997 Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci USA 94:13203–13208[Abstract/Free Full Text]
111. Dickson SE, Fraser HM 2000 Inhibition of early luteal angiogenesis by gonadotropin-releasing hormone antagonist treatment in the primate. J Clin Endocrinol Metab 85:2339–2344[Abstract/Free Full Text]
112. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E 1998 Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 95:10820–10825[Abstract/Free Full Text]
113. Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P, Perruchoud AP 1997 Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 16:398–406[Abstract]
114. Gloddek J, Pagotto U, Paez-Pereda M, Arzt E, Stalla GK, Renner U 1999 Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. J Endocrinol 160:483–490[Abstract]
115. Machein MR, Kullmer J, Ronicke V, Machein U, Krieg M, Damert A, Breier G, Risau W, Plate KH 1999 Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol 25:104–112[CrossRef][Medline]
116. Shifren JL, Mesiano S, Taylor RN, Ferrara N, Jaffe RB 1998 Corticotropin regulates vascular endothelial growth factor expression in human fetal adrenal cortical cells. J Clin Endocrinol Metab 83:1342–1347[Abstract/Free Full Text]
117. Arbiser JL, Karalis K, Viswanathan A, Koike C, Anand-Apte B, Flynn E, Zetter B, Majzoub JA 1999 Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol 113:838–842[CrossRef][Medline]
118. Greil W, Rafferzeder M, Bechtner G, Gartner R 1989 Release of an endothelial cell growth factor from cultured porcine thyroid follicles. Mol Endocrinol 3:858–867[Abstract/Free Full Text]
119. Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A, Persico MG 1997 Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15:2687–2698[CrossRef][Medline]
120. Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsumi K, Demura H, Yamaguchi S, Shibuya M 1995 Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 96:1295–1302
121. Soh EY, Sobhi SA, Wong MG, Meng YG, Siperstein AE, Clark OH, Duh QY 1996 Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 120:944–947[CrossRef][Medline]
122. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM 1997 Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276:1706–1709[Abstract/Free Full Text]
123. Hellstrom A, Svensson E, Carlsson B, Niklasson A, Albertsson-Wikland K 1999 Reduced retinal vascularization in children with growth hormone deficiency. J Clin Endocrinol Metab 84:795–798[Abstract/Free Full Text]
124. Gould J, Aramburo C, Capdevielle M, Scanes CG 1995 Angiogenic activity of anterior pituitary tissue and growth hormone on the chick embryo chorio-allantoic membrane: a novel action of GH. Life Sci 56:587–594[CrossRef][Medline]
125. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, Van-Obberghen E 2000 Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem 275:21695–21702[Abstract/Free Full Text]
126. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR 1999 Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5:1390–1395[CrossRef][Medline]
127. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy NS, Goldberg MA, D’Amato RJ, Adamis AP 1997 Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46:1619–1626[Abstract]
128. Goad DL, Rubin J, Wang H, Tashjian Jr AH, Patterson C 1996 Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137:2262–2268[Abstract]
129. Bermont L, Lamielle F, Fauconnet S, Esumi H, Weisz A, Adessi GL 2000 Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinoma cells. Int J Cancer 85:117–123[CrossRef][Medline]
130. Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC 1998 Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 58:348–351[Abstract/Free Full Text]
131. Lee OH, Bae SK, Bae MH, Lee YM, Moon EJ, Cha HJ, Kwon YG, Kim KW 2000 Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br J Cancer 82:385–391[CrossRef][Medline]
132. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B 1998 Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1/ARNT. EMBO J 17:5085–5094[CrossRef][Medline]
133. Esbrit P, Alvarez-Arroyo MV, De Miguel F, Martin O, Martinez ME, Caramelo C 2000 C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol 11:1085–1092[Abstract/Free Full Text]
134. Deckers MM, Karperien M, van der Bent C, Yamashita T, Papapoulos SE, Lowik CW 2000 Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 141:1667–1674[Abstract/Free Full Text]
135. Wang DS, Yamazaki K, Nohtomi K, Shizume K, Ohsumi K, Shibuya M, Demura H, Sato K 1996 Increase of vascular endothelial growth factor mRNA expression by 1,25 dihydroxyvitamin D3 in human osteoblast-like cells. J Bone Miner Res 11:472–479[Medline]
136. Akino K, Ohtsuru A, Kanda K, Yasuda A, Yamamoto T, Akino Y, Naito S, Kurpkawa M, Iwahori N, Yamashita S 2000 Parathyroid hormone related peptide is a potent angiogenic factor. Endocrinology 141:4313–4316[Abstract/Free Full Text]
137. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell’Era P, Nico B, Roncali L, Dammacco F 1999 Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627–2636[Abstract/Free Full Text]
138. Xin X, Yang S, Kowalski J, Gerritsen ME 1999 Peroxisome proliferator-activated receptor ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116–9121[Abstract/Free Full Text]
139. Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H, Nishizawa Y 2000 Peroxisome proliferator-activated receptor- agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 271:571–574[CrossRef][Medline]
140. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA 1995 Antiintegrin v ß 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815–1822
141. Holmgren L, Bicknell R 1997 Inhibition of tumor angiogenesis and the induction of tumor dormancy. In: Bicknell R, Lewis CE, Ferrara N, eds. Tumor angiogenesis. Oxford, UK: Oxford University Press; 301–307
142. Jekunen AP, Kairemo KJA 1997 Inhibition of malignant angiogenesis. Cancer Treat Rev 23:263–286[CrossRef][Medline]
143. O’Reilly M, Rosenthal R, Sage EH, Smith S, Holmgren L, Moses M, Shing Y, Folkman J 1993 The suppression of tumor metastases by a primary tumor. Surg Forum 44:474–476
144. O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J 1994 Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315–328[CrossRef][Medline]
145. Holmgren L, O’Reilly MS, Folkman J 1995 Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149–153[CrossRef][Medline]
146. O’Reilly MS, Holmgren L, Chen C, Folkman J 1996 Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689–692[CrossRef][Medline]
147. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC, Soff GA 1996 Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 56:4887–4890[Abstract/Free Full Text]
148. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA 1997 The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 94:10868–10872[Abstract/Free Full Text]
149. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV 1999 Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96:2811–2816[Abstract/Free Full Text]
150. Griscelli F, Li H, Cheong C, Opolon P, Bennaceur-Griscelli A, Vassal G, Soria J, Soria C, Lu H, Perricaudet M, Yeh P 2000 Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci USA 97:6698–6703[Abstract/Free Full Text]
151. Sacco MG, Caniatti M, Cato EM, Frattini A, Chiesa G, Ceruti R, Adorni-F, Zecca L, Scanziani E, Vezzoni P 2000 Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. Cancer Res 60:2660–2665[Abstract/Free Full Text]
152. Drixler TA, Rinkes IH, Ritchie ED, van-Vroonhoven TJ, Gebbink MF, Voest EE 2000 Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 60:1761–1765[Abstract/Free Full Text]
153. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285[CrossRef][Medline]
154. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG 2001 Thrombospondins and tumor angiogenesis. Trends Mol Med 7:401–407[CrossRef][Medline]
155. Iruela-Arispe ML, Vazquez F, Ortega MA 1999 Antiangiogenic domains shared by thrombospondins and metallospondins, a new family of angiogenic inhibitors. Ann N Y Acad Sci 886:58–66[CrossRef][Medline]
156. Dameron KM, Volpert OV, Tainsky MA, Bouck N 1994 Control of angiogenesis in fibroblasts by p53 regulation. Science 265:1582–1584[Abstract/Free Full Text]
157. Woltering EA, Barrie R, O’Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J 1991 Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50:245–251[CrossRef][Medline]
158. Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS 1993 Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 55:446–450[CrossRef][Medline]
159. Danesi R, Agen C, Benelli U, Di Paolo A, Nardini D, Bocci G, Basolo F, Campagni A, Del Tacca M 1997 Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201–995). Clin Cancer Res 3:265–272[Abstract]
160. Patel PC, Barrie R, Hill N, Landeck S, Kurozawa D, Woltering EA 1994 Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 116:1148–1152[Medline]
161. Garcia de la Torre N, Wass JAH, Turner HE 2002 Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 57:425–441[CrossRef][Medline]
162. Struman I, Bentzien F, Lee H, Mainfroid V, D’Angelo G, Goffin V, Weiner RI, Martial JA 1999 Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 96:1246–1251[Abstract/Free Full Text]
163. Merkle CJ, Schuler LA, Schaeffer RC, Gribbon JM, Montgomery DW 2000 Structural and functional effects of high prolactin levels on injured endothelial cells. Endocrine 13:37–46[CrossRef][Medline]
164. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI 1993 The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133:1292–1299[Abstract/Free Full Text]
165. Khurana S, Liby K, Buckley AR, Ben-Jonathan N 1999 Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic C-terminal 16 k fragment by thrombin. Endocrinology 140:4127–4132[Abstract/Free Full Text]
166. Rymaszewski Z, Cohen RM, Chomczynski P 1991 Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. Proc Natl Acad Sci USA 88:617–621[Abstract/Free Full Text]
167. Ferrara N, Clapp C, Weiner R 1991 The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129:896–900[Abstract/Free Full Text]
168. Baldocchi RA, Tan L, King DS, Nicoll CS 1993 Mass spectrometric analysis of the fragments produced by cleavage and reduction of rat prolactin: evidence that the cleaving enzyme is cathepsin D. Endocrinology 133:935–938[Abstract/Free Full Text]
169. Clapp C, Sears PS, Russell DH, Richards J, Levay-Young BK, Nicoll CS 1988 Biological and immunological characterization of cleaved and 16K forms of rat prolactin. Endocrinology 122:2892–2898[Abstract/Free Full Text]
170. Clapp C, Torner L, Gutierrez-Ospina G, Alcantara E, Lopez-Gomez FJ, Nagano M, Kelly PA, Mejia S, Morales MA, Martinez de la Escalera G 1994 The prolactin gene is expressed in the hypothalamic-neurohypophyseal system and the protein is processed into a 14-kDa fragment with activity like 16-kDa prolactin. Proc Natl Acad Sci USA 91:10384–10388[Abstract/Free Full Text]
171. Clapp C, Weiner RI 1992 A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 130:1380–1386[Abstract/Free Full Text]
172. D’Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI 1999 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 13:692–704[Abstract/Free Full Text]
173. D’Angelo G, Struman I, Martial J, Weiner RI 1995 Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 92:6374–6378[Abstract/Free Full Text]
174. Sinha YN, Gilligan TA 1984 A cleaved form of prolactin in the mouse pituitary gland: identification and comparison of in vitro synthesis and release in strains with high and low incidences of mammary tumors. Endocrinology 1140:2046–2053
175. Torner L, Mejia S, Lopez-Gomez FJ, Quintanar A, Martinez de la Escalera G, Clapp C 1995 A 14-kilodalton prolactin-like fragment is secreted by the hypothalamo-neurohypophyseal system of the rat. Endocrinology 136:5454–5460[Abstract]
176. Sinha YN, Gilligan TA, Lee DW, Hollingsworth D, Markoff E 1985 Cleaved prolactin: evidence for its occurrence in human pituitary gland and plasma. J Clin Endocrinol Metab 60:239–243[Abstract/Free Full Text]
177. Murphy G, Docherty AJ 1992 The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7:120–125
178. Stetler-Stevenson WG, Liotta LA, Kliener DE 1993 Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:1434–1441[Abstract]
179. Stetler-Stevenson WG, Krutsch HC, Liotta LA 1989 Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 264:17374–17378[Abstract/Free Full Text]
180. Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C 1994 Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase family. Cancer Res 54:2091–2094[Abstract/Free Full Text]
181. Ponton A, Coulombe B, Skup D 1991 Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased collagenase activity. Cancer Res 51:2138–2143[Abstract/Free Full Text]
182. Liotta LA, Steeg PS, Stetler-Stevenson WG 1991 Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327–336[CrossRef][Medline]
183. Zucker S, Lysik RM, Zarrabi MH, Moll U 1993 Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53:140–146[Abstract/Free Full Text]
184. Ballin M, Gomez SE, Sinha CC, Thorgeirsson UP 1988 Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype. Biochem Biophys Res Commun 154:832–838[CrossRef][Medline]
185. Bernhard ED, Gruber SB, Muschel RJ 1994 Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91:4293–4297[Abstract/Free Full Text]
186. Hua J, Muschel R 1996 Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 56:5279–5284[Abstract/Free Full Text]
187. Nakajima M, Welch D, Wynn D, Tsuruo Y, Nocolson G 1993 Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 53:5802–5807[Abstract/Free Full Text]
188. Watanabe H, Nakanishi I, Yamashita K, Hayakawa T, Okada Y 1993 Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. J Cell Sci 104:991–999[Abstract]
189. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR 1996 Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin’s lymphomas in humans. Br J Cancer 73:1401–1408[Medline]
190. Sang QX 1998 Complex role of matrix metalloproteinases in angiogenesis. Cell Res 8:171–177[Medline]
191. Jackson CJ, Nguyen M 1997 Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int J Biochem Cell Biol 29:1167–1177[CrossRef][Medline]
192. Anand-Apte B, Pepper MS, Voest E, Montesano R, Olsen B, Murphy G, Apte SS, Zetter B 1997 Inhibition of angiogenesis by tissue-inhibitor of metalloproteinase-3. Opthalmol Vis Sci 38:817–823
193. Takigawa M, Nishida Y, Suzuki F, Kishi J, Yamashita K, Hayakawa T 1990 Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem Biophys Res Commun 171:1264–1271[CrossRef][Medline]
194. Talbot DC, Brown PD 1996 Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32:2528–2533[CrossRef]
195. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S 1999 Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59:1252–1258[Abstract/Free Full Text]
196. Patterson BC, Sang QA 1997 Angiostatin-converting enzyme activities of human matrilysin and gelatinase B/type IV collagenase. J Biol Chem 272:28823–28825[Abstract/Free Full Text]
197. Hoshino M, Takahashi M, Takai Y, Sim J 1999 Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 104:356–363[CrossRef][Medline]
198. Coughlan AR, Robertson DH, Bennett D, May C, Beynon RJ, Carter SD 1998 Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis. Vet Rec 143:219–223[Abstract/Free Full Text]
199. Damjanovski S, Puzianowska-Kuznicka M, Ishuzuya-Oka A, Shi YB 2000 Differential regulation of three thyroid hormone-responsive matrix metalloproteinase genes implicates distinct functions during frog embryogenesis. FASEB J 14:503–510[Abstract/Free Full Text]
200. Anne-Valerie R, Christelle D, Yannick F, Norbert P, Marc P, Dominique H 2000 Human growth hormone stimulates proteinase activities of rabbit bone cells via IGF-I. Biochem Biophys Res Commun 268:875–881[CrossRef][Medline]
201. Mira E, Manes S, Lacalle RA, Marquez G, Martinez AC 1999 Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 140:1657–1664[Abstract/Free Full Text]
202. Long L, Navab R, Brodt P 1998 Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res 58:3243–3247[Abstract/Free Full Text]
203. McClelland P, Onyia JE, Miles RR, Tu Y, Liang J, Harvey AK, Chandrasekhar S, Hock JM, Bidwell JP 1998 Intermittent administration of parathyroid hormone (1–34) stimulates matrix metalloproteinase 9 (MMP 9) expression in rat long bone. J Biol Biochem 70:391–401
204. Kawashima Ohya Y, Satakeda H, Kuruta Y, Kawamoto T, Yan W, Akagawa Y, Hayakawa T, Noshiro M, Okada Y, Nakamura S, Kato Y 1998 Effects of parathyroid hormone (PTH) and PTH-related peptide on expressions of matrix metalloproteinase-2, -3, and -9 in growth plate chondrocyte cultures. Endocrinology 139:2120–2127[Abstract/Free Full Text]
205. Fowlkes JL, Thrailkill KM, Serra DM, Suzuki K, Nagase H 1995 Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res 6:255–263[CrossRef][Medline]
206. Rajah R, Nunn SE, Herrick DJ, Grunstein MM, Cohen P 1996 Leukotriene D4 induces MMP-1 which functions as an IGFBP protease in human airway smooth muscle cells. Am J Physiol 271:1014–1022
207. Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, Martinez AC 1999 The matrix metalloproteinase 9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274:6935–6945[Abstract/Free Full Text]
208. Martin DC, Fowlkes JL, Babic B, Khokha R 1999 Insulin-like growth factor II signalling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP 1. J Cell Biol 146:881–892[Abstract/Free Full Text]
209. Wu HB, Lee CY, Rechler MM 1999 Proteolysis of insulin-like growth factor binding protein-3 in serum from pregnant, non-pregnant and fetal rats by matrix metalloproteinases and serine proteases. Horm Metab Res 31:186–191[Medline]
210. Ogawa T, Takayama K, Takakura N, Kitano S, Ueno H 2002 Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 9:633–640[CrossRef][Medline]
211. Ding L, Donate F, Parry GCN, Guan X, Maher P, Levin EG 2002 Inhibition of cell migration and angiogenesis by the amino terminal fragment of 24 kDa basic fibroblast growth factor. J Biol Chem 277:31056–31061[Abstract/Free Full Text]
212. Dhanabal M, LaRochelle WJ, Jeffers M, Herrmann J, Rastelli L, McDonald WF, Chillakuru RA, Yang M, Boldog FL, Padigaru M, McQueeney KD, Wu F, Minskoff SA, Shimkets RA, Lichenstein HS 2002 Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties. Cancer Res 62:3834–3841[Abstract/Free Full Text]
213. Presta M, Belleri M, Vacca A, Ribatti D 2002 Anti-angiogenic activity of the purine analog 6-thioguanine. Leukemia 16:1490–1499[CrossRef][Medline]
214. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmel E, Nakada MT 2002 Multiple roles for platelet GPIIb/IIIa and vß3 integrins in tumor growth, angiogenesis and metastasis. Cancer Res 62:2824–2833[Abstract/Free Full Text]
215. Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti P, Roccabianca P, Scanziani E, Nicoletti MI, Bombardelli E, Morazzonni P, Riva A, Giavazzi R 2002 Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 8:1182–1188[Abstract/Free Full Text]
216. Masferrer JL, Koki A, Seibert K 1999 COX-2 inhibitors. A new class of anti-angiogenic agents. Ann N Y Acad Sci 889:84–86[CrossRef][Medline]
217. Schechter J 1972 Ultrastructural changes in the capillary bed of human pituitary tumors. Am J Pathol 67:109–126[Medline]
218. Jugenburg M, Kovacs K, Stefaneanu L, Scheithauer BW 1995 Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocr Pathol 6:115–124[Medline]
219. Turner HE, Nagy Zs, Gatter KC, Esiri MM, Harris AL, Wass JAH 2000 Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 85:1159–1162[Abstract/Free Full Text]
220. Turner HE, Moore NR, Byrne JV, Wass JAH 1998 Pituitary, thyroid and adrenal incidentalomas. Endocr Cancer 5:131–150
221. Elias KA, Weiner RI 1984 Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. Proc Natl Acad Sci USA 81:4549–4553[Abstract/Free Full Text]
222. Ferrara N, Winer J, Henzel WJ 1992 Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: identification as leukemia inhibitory factor. Proc Natl Acad Sci USA 89:698–702[Abstract/Free Full Text]
223. Erroi A, Bassetti M, Spada A, Giannattasio G 1986 Microvasculature of human micro- and macroprolactinomas. A morphological study. Neuroendocrinology 43:159–165[Medline]
224. Pawlikowski M, Pisarek H, Jaranowska M 1997 Immunocytochemical investigations on the vascularization of pituitary adenomas. Endocr Pathol 8:189–193[Medline]
225. Turner HE, Nagy Zs, Gatter KC, Esiri MM, Harris AL, Wass JAH 2000 Angiogenesis in pituitary adenomas: relationship to endocrine function, treatment and outcome. J Endocrinol 165:475–481[Abstract]
226. Turner HE, Nagy ZS, Gatter KC, Esiri MM, Wass JAH, Harris AL 2000 Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumor behaviour. Br J Cancer 82:1441–1445[Medline]
227. Delgrange E, Trouillas J, Maiter D, Donckier J, Tournaire J 1997 Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107[Abstract/Free Full Text]
228. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J 1996 Long-term follow-up of patients with hyperprolactinemia. Clin Endocrinol (Oxf) 45:299–303[CrossRef][Medline]
229. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoeffer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D 2001 The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569–574[CrossRef][Medline]
230. Ito M, Enomoto H, Villadolid MC, Ohtsuru A, Namba H, Sekine I, Yamashita S 1993 Expression of parathyroid hormone related peptide in human pituitary tumors. J Clin Pathol 46:682–683[Abstract/Free Full Text]
231. Vartainen RK, Weidner N 1994 Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 144:1188–1194[Abstract]
232. Vermeulen PB, Dirix LY, Libura J, Vanhoolst IF, Van Marck E, Oosterom AT 1997 Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density. Microvasc Res 54:88–92[CrossRef][Medline]
233. Nor JE, Christensen J, Mooney DJ, Polverini PJ 1999 Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154:375–384[Abstract/Free Full Text]
234. Popa G, Fielding U 1930 The vascular link between the pituitary and the hypothalamus. Lancet 2:238–240[CrossRef]
235. Popa G, Fielding U 1931 A portal circulation from the pituitary to the hypothalamic region. J Anat 65:88–91
236. Harris GW, Jacobsohn D 1952 Functional grafts of anterior pituitary gland. Proc Royal Soc Ser B 139:273–276
237. Stanfield JP 1960 The blood supply of the human pituitary gland. J Anat 94:257–273[Medline]
238. Bergland RM, Page RB 1979 Pituitary brain vascular relations. A new paradigm. Science 204:18–24[Abstract/Free Full Text]
239. Powell DF, Baker HL, Laws ER 1974 The primary angiographic findings in pituitary adenomas. Radiology 110:589–595[Medline]
240. Yuh WTC, Fisher DJ, Nguyen HD, Tali ET, Gao F, Simonson TM, Schlechte J 1994 Sequential MR enhancement pattern in normal pituitary gland and pituitary adenoma. Am J Neuroradiol 15:101–108[Abstract]
241. Lees PD, Pickard JD 1987 Hyperprolactinaemia, intrasellar pituitary tissue pressure and the pituitary stalk compression system. J Neurosurg 67:192–196[Medline]
242. Gorczyca W, Hardy J 1988 Microadenomas of the human pituitary and their vascularization. Neurosurgery 22:1–6[Medline]
243. Schechter J, Goldsmith P, Wilson C, Weiner R 1988 Morphological evidence for the presence of arteries in human prolactinomas. J Clin Endocrinol Metab 67:713–719[Abstract/Free Full Text]
244. Terayama N, Terada T, Nakanuma Y 1996 An immunohistochemical study of tumor vessels in metastatic liver cancers and the surrounding liver tissue. Histopathology 29:37–43[CrossRef][Medline]
245. Kovacs K, Horvath E 1973 Vascular alterations in adenomas of human pituitary glands. Angiologica 10:299–309[Medline]
246. Farnoud MR, Lissak B, Kujas M, Peillon F, Racadot J, Li JY 1992 Specific alterations of the basement membrane and stroma antigens in human pituitary tumors in comparison with the normal anterior pituitary. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 421:449–455[CrossRef][Medline]
247. Monnet F, Elias KA, Fagin K, Neill A, Goldsmith P, Weiner RI 1984 Formation of a direct arterial blood supply to the anterior pituitary gland following complete or partial interruption of the hypophyseal portal vessels. Neuroendocrinology 39:251–255[CrossRef][Medline]
248. Elias KA, Weiner RI 1987 Inhibition of estrogen-induced anterior pituitary enlargement and arteriogenesis by bromocriptine in Fischer 344 rats. Endocrinology 120:617–621[Abstract/Free Full Text]
249. Schechter J, Ahmad N, Elias K, Weiner R 1987 Estrogen-induced tumors: changes in the vasculature in two strains of rat. Am J Anat 179:315–323[CrossRef][Medline]
250. Tiboldi T, Nemassanyi Z, Csernay I, Kovacs K 1967 Effect of estrogen on pituitary blood flow in rat. Endocrinol Exp 1:73–77
251. Rinehart JF, Farquhar MG 1953 Electron-microscopic studies of the anterior pituitary gland. J Histochem Cytochem 1:93–113[Abstract]
252. Nakajama T, Yamaguchi H, Takahashi K 1980 S100 protein in folliculostellate cells of the rat pituitary anterior lobe. Brain Res 191:523–531[CrossRef][Medline]
253. Allaerts W, Jeucken PH, Hofland LJ, Drexhage HA 1991 Morphological, immunohistochemical and functional homologies between pituitary folliculo-stellate cells and lymphoid dendritic cells. Acta Endocrinol (Copenh) 125(Suppl 1):92–97
254. Allaerts W, Carmeliet P, Denef C 1990 New perspectives in the function of pituitary folliculostellate cells. Mol Cell Endocrinol 71:73–81[CrossRef][Medline]
255. Shiotani Y 1980 An electron microscopic study on stellate cells in the rabbit adenohypophysis under various endocrine conditions. Cell Tissue Res 213:237–246[Medline]
256. Shirasawa N, Kihara H, Yamaguchi S, Yoshimura F 1983 Pituitary folliculostellate cells immunostained with S-100 protein antiserum in postnatal, castrated and thyroidectomised rats. Cell Tissue Res 231:235–249[Medline]
257. Schechter J, Ahmad N, Weiner R 1988 Activation of anterior pituitary folliculostellate cells in the formation of estrogen-induced prolactin-secreting tumors. Neuroendocrinology 48:569–576[Medline]
258. Ferrara N, Fujii DK, Goldsmith PC, Widdicombe JH, Weiner RI 1987 Transport epithelial characteristics of cultured bovine pituitary follicular cells. Am J Physiol 252:E304–E312
259. Ferrara N, Schweigerer L, Neufeld G, Mitchell R, Gospodarowicz D 1987 Pituitary follicular cells produce basic fibroblast growth factor. Proc Natl Acad Sci USA 84:5773–5777[Abstract/Free Full Text]
260. Ferrara N, Henzel WJ 1989 Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851–858[CrossRef][Medline]
261. Iwaki T, Kondo A, Takeshita I, Nakagaki H, Kitamura K, Tateishi J 1986 Proliferating potential of folliculo-stellate cells in human pituitary adenomas. Acta Neuropathol 71:233–242[CrossRef][Medline]
262. Turner HE, Nagy Zs, Esiri MM, Harris AL, Wass JAH Vascular endothelial growth factor is related to angiogenesis in pituitary tumors. Proc 6th International Pituitary Congress, Long Beach, CA, 1999, p 103 (Abstract)
263. Höfler H, Walter GF, Denk H 1984 Immunohistochemistry of folliculostellate cells in normal human adenohypophysis and in pituitary adenomas. Acta Neuropathol (Berl) 65:35–40[CrossRef][Medline]
264. Nishikawa R, Cheng S, Nagashima R, Su Huang H, Cavenee WK, Matsutani M 1998 Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (Berl) 96:453–462[CrossRef][Medline]
265. Lauriola L, Cocchia D, Seninelli S, Maggiano N, Maira G, Michetti F 1984 Immunohistochemical detection of folliculostellate cells in human pituitary adenomas. Virchows Arch B Cell Pathol Incl Mol Pathol 47:189–197[Medline]
266. Long J, Tsumanuma I, Ruebel K, Bayliss KH, Lloyd RV 2001 Analysis of homogeneous populations of anterior pituitary folliculostellate cells by laser capture microdissection and reverse transcription polymerase chain reaction. Endocrinology 142:1703–1709[Abstract/Free Full Text]
267. Banerjee SK, Sarkar DK, Weston AP, De A, Campbell DR 1997 Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 18:1155–1161[Abstract/Free Full Text]
268. Ochoa AL, Mitchner NA, Paynter CD, Morris RE, Ben-Jonathan N 2000 Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. J Endocrinol 165:483–492[Abstract]
269. Jabbour HN, Boddy SC, Lincoln GA 1997 Pattern and localisation of expression of vascular endothelial growth factor and its receptor flt-1 in the ovine pituitary gland: expression is independent of hypothalamic control. Mol Cell Endocrinol 134:91–100[CrossRef][Medline]
270. Vidal S, Kovacs K, Cohen SM, Stefaneanu L, Lloyd RV, Scheithauer BW 1999 Vascular endothelial growth factor (VEGF) expression in nontumorous human pituitaries. Endocr Pathol 10:109–122[CrossRef]
271. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L 1999 Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10:229–235[Medline]
272. Turner HE, Nagy ZS, Bromhall L, Esiri MM, Harris AL, Wass JAH 2000 Vascular endothelial growth factor is elevated in patients with pituitary tumors. J Endocrinol 161:P215
273. Vidal S, Oliveira MC, Kovacs K, Scheithauer BW, Lloyd R 2000 Immunolocalization of vascular endothelial growth factor in the GH3 cell line. Cell Tissue Res 300:83–88[Medline]
274. Green VL, Eycott KR, Speirs V, For P, Landolt AM, Mathew B, Atkin SL 1999 The expression of vascular endothelial growth factor in normal and adenomatous human anterior pituitary. J Endocrinol 160:P132
275. McCabe CJ, Khaira JS, Sheppard MC, Franklyn JA, Gittoes NJL 2000 Pituitary tumor transforming gene, basic fibroblast growth factor, and vascular endothelial growth factor expression in sporadic pituitary adenomas. Pituitary 3:22
276. Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV 2001 Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 438:595–602[CrossRef][Medline]
277. Lohrer P, Gloddek J, Hopfner U, Losa M, Uhl E, Pagotto U, Stalla GK, Renner U 2001 Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 74:95–105[CrossRef][Medline]
278. Silverlight JJ, Prysor Jones RA, Jenkins JS 1990 Basic fibroblast growth factor in human pituitary tumors. Clin Endocrinol (Oxf) 32:669–676[Medline]
279. Zimmering MB, Katsumata N, Sato Y, Brandi ML, Aurbach GD, Marx SJ, Friesen HG 1993 Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: relation to pituitary tumor. J Clin Endocrinol Metab 76:1182–1187[Abstract]
280. Li Y, Koga M, Kasayama S, Matsumoto K, Arita N, Hayakawa T, Sato B 1992 Identification and characterization of high molecular weight forms of basic fibroblast growth factor in human pituitary adenomas. J Clin Endocrinol Metab 75:1436–1441[Abstract]
281. Suzui H, Takahashi JA, Fukumoto M, Hashimoto N, Itoh N, Hatanaka M, Kikuchi H 1994 Immunohistochemical study for basic fibroblast growth factor and fibroblast growth factor receptor I in pituitary adenomas. Neurosci Lett 171:192–196[CrossRef][Medline]
282. Ezzat S, Smyth HS, Ramyar L, Asa SL 1995 Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. J Clin Endocrinol Metab 80:878–884[Abstract]
283. Black EG, Logan A, Davis JR, Sheppard MC 1990 Basic fibroblast growth factor affects DNA synthesis and cell function and activates multiple signalling pathways in rat thyroid FRTL-5 and pituitary GH3 cells. J Endocrinol 127:39–46[Abstract/Free Full Text]
284. Porter TE, Wiles CD, Frawley LS 1994 Stimulation of lactotrope differentiation in vitro by fibroblast growth factor. Endocrinology 134:164–168[Abstract/Free Full Text]
285. Pei L, Melmed S 1997 Isolation and characterization of a pituitary tumor transforming gene (PTTG). Mol Endocrinol 11:433–441[Abstract/Free Full Text]
286. Zhang Z, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S 1999 Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84:761–767[Abstract/Free Full Text]
287. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S 1999 Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321[CrossRef][Medline]
288. Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S 2001 Human pituitary tumor transforming gene induces angiogenesis. J Clin Endocrinol Metab 86:867–874[Abstract/Free Full Text]
289. Akita S, Webster J, Ren S, Takono H, Said J, Zand O, Melmed S 1995 Human and murine pituitary expression of leukemia inhibitory factor. J Clin Invest 95:1288–1298
290. Akita S, Readhead C, Stefaneanu L, Fine J, Tampanaru Sarmesiu A, Kovacs K, Melmed S 1997 Pituitary-directed leukemia inhibitory factor transgene forms Rathke’s cleft cysts and impairs adult pituitary function. A model for human pituitary Rathke’s cysts. J Clin Invest 99:2462–2469[Medline]
291. Zou H, McGarry TJ, Bernal T, Kirschner MW 1999 Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285:418–422[Abstract/Free Full Text]
292. Ramos-Morales F, Dominguez A, Romero F, Luna R, Multon M, Pintor-Toro JA, Tortolero M 2000 Cell cycle regulated expression and phosphorylation of hPTTG proto-oncogene product. Oncogene 19:403–409[CrossRef][Medline]
293. Qian X, Kulig E, Jin L, Lloyd RV 1998 Expression of D-type cyclins in normal and neoplastic rat pituitary. Endocrinology 139:2058–2067[Abstract/Free Full Text]
294. Kawamoto H, Uozumi T, Kawamtot K, Arita K, Yano T, Hirohata T 1996 Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir (Wien) 138:390–395[CrossRef][Medline]
295. Pereda MP, Ledda MF, Goldberg V, Chervin A, Carrizo G, Molina H, Muller A, Renner U, Podhajcer OO, Arzt E, Stalla GK 2000 High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J Clin Endocrinol Metab 84:263–269
296. Turner HE, Nagy ZS, Esiri MM, Harris AL, Wass JAH 2000 Role of matrix metalloproteinase 9 in pituitary tumors. J Clin Endocrinol Metab 85:2931–2935[Abstract/Free Full Text]
297. Sehgal I, Thompson TC 1998 Neuropeptides induce Mr 92,000 type IV collagenase (matrix-metalloproteinase 9) activity in human prostate cancer cell lines. Cancer Res 58:4288–4291[Abstract/Free Full Text]
298. Beitner-Johnson D, Millhorn DE 1998 Hypoxia induces phosphorylation of the cAMP response element binding protein by a novel signalling mechanism. J Biol Chem 273:19834–19839[Abstract/Free Full Text]
299. Herber B, Truss M, Beato M, Muller R 1994 Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 9:1295–1304[Medline]
300. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB, Fini ME 2000 Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 275:10405–10412[Abstract/Free Full Text]
301. Takechi A, Uozumi T, Kawamoto K, Ito A, Kurisu K, Sudo K 1994 Inhibitory effect of TNP-470, a new anti-angiogenic agent, on the estrogen induced rat pituitary tumors. Anticancer Res 14:157–162[Medline]
302. Stepien H, Grochal M, Zielinski KW, Mucha S, Kunert-Radek J, Kulig A, Stawowy A, Pisarek H 1996 Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. J Endocrinol 150:99–106[Abstract/Free Full Text]
303. Sasano H, Ohashi Y, Suzuki T, Nagura H 1998 Vascularity in human adrenal cortex. Mod Pathol 11:329–333[Medline]
304. Liu Q, Djuricin G, Staren ED, Gattuso P, Gould VE, Shen J, Saclarides T, Rubin DB, Prinz RA 1996 Tumor angiogenesis in pheochromocytomas and paragangliomas. Surgery 120:938–941[CrossRef][Medline]
305. Fan L, Iseki S 1998 Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch Histol Cytol 61:17–28[Medline]
306. Jyung RW, LeClair EE, Bernat RA, Kang TS, Ung F, McKenna MJ, Tuan RS 2000 Expression of angiogenic growth factors in paragangliomas. Laryngoscope 110:161–167[CrossRef][Medline]
307. Kolomecki K, Stepien H, Narebski JM 2000 Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumors. Cytobios 101:55–64[Medline]
308. Basile DP, Holzwarth MA 1993 Basic fibroblast growth factor may mediate proliferation in the compensatory adrenal growth response. Am J Physiol 265:R1253–R1261
309. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D 1987 Basic fibroblast growth factor: production and growth stimulation in cultured adrenal cortex cells. Endocrinology 120:796–800[Abstract/Free Full Text]
310. Armelin HA, Lotfi CF 1999 Control of the adrenocortical cell cycle: interaction between FGF2 and ACTH. Braz J Med Biol Res 32:841–843[Medline]
311. Clarke MR, Weyant RJ, Watson CG, Carty SE 1998 Prognostic markers in pheochromocytoma. Hum Pathol 29:522–526[CrossRef][Medline]
312. Statuto M, Ennas MG, Zamboni G, Bonetti F, Pea M, Bernardello F, Pozzi A, Rusnati M, Gualandris A, Presta M 1993 Basic fibroblast growth factor in human pheochromocytoma: a biochemical and immunohistochemical study. Int J Cancer 53:5–10[Medline]
313. Kjellman M, Enberg U, Hoog A, Larsson C, Holst M, Farnebo LO, Sato H, Backdahl M 1999 Gelatinase A and membrane-type 1 matrix metalloproteinase mRNA: expressed in adrenocortical cancers but not in adenomas. World J Surg 23:237–242[CrossRef][Medline]
314. Iliopoulos O, Levy AP, Jiang C, Kaelin Jr WG, Goldberg MA 1996 Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93:10595–10599[Abstract/Free Full Text]
315. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D 1996 Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56:2299–2301[Abstract/Free Full Text]
316. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, Linehan WM 1996 Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93:10589–10594[Abstract/Free Full Text]
317. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ 1999 The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275[CrossRef][Medline]
318. Stebbins CE, Kaelin WG, Pavletich NP 1999 Structure of the VHL-elongin C-elongin B complex: implications for VHL tumor suppressor function. Science 284:455–461[Abstract/Free Full Text]
319. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG 2000 Ubiquination of hypoxia-inducible factor requires direct binding to the ß-domain of the von Hippel Lindau protein. Nat Cel Biol 2:423–427
320. Los M, Zeamari S, Foekens JA, Gebbink MF, Voest EE 1999 Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res 59:4440–4445[Abstract/Free Full Text]
321. Bar M, Friedman E, Jakobovitz O, Leibowitz G, Lerer I, Abeliovich D, Gross DJ 1997 Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. Clin Endocrinol (Oxf) 47:707–712[CrossRef][Medline]
322. Semenza GL, Wang GL 1992 A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447–5454[Abstract/Free Full Text]
323. Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL 1998 The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12:3320–3324[Abstract/Free Full Text]
324. Mashour GA, Wang HL, Cabal-Manzano R, Wellstein A, Martuza RL, Kurtz A 1999 Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1. J Invest Dermatol 113:398–402[CrossRef][Medline]
325. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, Le-Bouc Y 1994 Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78:1444–1453[Abstract]
326. Gicquel C, Bertherat J, Le-Bouc Y, Bertagna X 2000 Pathogenesis of adrenocortical incidentalomas and genetic syndromes associated with adrenocortical neoplasms. Endocrinol Metab Clin North Am 29:1–13[CrossRef][Medline]
327. Nguyen M, Shing Y, Folkman J 1994 Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res 47:31–40[CrossRef][Medline]
328. Harris AL 2000 von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. Oncologist 5(Suppl 1):32–36
329. Gross DJ, Reibstein I, Weiss L, Slavin S, Stein I, Neeman M, Abramovitch R, Benjamin LE 1999 The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice. Clin Cancer Res 5:3669–3675[Abstract/Free Full Text]
330. Wollman SH, Herveg JP, Zeligs JD, Ericson LE 1978 Blood capillary enlargement during the development of thyroid hyperplasia in the rat. Endocrinology 103:2306–2314[Abstract/Free Full Text]
331. Goodman AL, Rone JD 1987 Thyroid angiogenesis: endotheliotropic chemoattractant activity from rat thyroid cells in culture. Endocrinology 121:2131–2140[Abstract/Free Full Text]
332. Iitaka M, Miura S, Yamanaka K, Kawasaki S, Kitahama S, Kawakami Y, Kakinuma S, Oosuga I, Wada S, Katayama S 1998 Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 83:3908–3912[Abstract/Free Full Text]
333. Akslen LA, Livolsi VA 2000 Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol 31:439–442[CrossRef][Medline]
334. Goldenberg JD, Portugal LG, Wenig BL, Ferrer K, Wu JC, Sabnani J 1998 Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density. Head Neck 20:152–158[CrossRef][Medline]
335. Segal K, Shpitzer T, Feinmesser M, Stern Y, Feinmesser R 1996 Angiogenesis in follicular tumors of the thyroid. J Surg Oncol 63:95–98[CrossRef][Medline]
336. Herrmann G, Schumm-Draeger PM, Muller C, Atai E, Wenzel B, Fabian T, Usadel KH, Hubner K 1994 T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. J Cancer Res Clin Oncol 120:651–656[CrossRef][Medline]
337. Ishiwata T, Iino Y, Takei H, Oyama T, Morishita Y 1998 Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep 5:1343–1348[Medline]
338. Dhar DK, Kubota H, Kotoh T, Tabara H, Watanabe R, Tachibana M, Kohno H, Nagasue N 1998 Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am J Surg 176:442–447[CrossRef][Medline]
339. Fontanini G, Vignati S, Pacini F, Pollina L, Basolo F 1996 Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol 9:636–641[Medline]
340. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH 1997 Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741–3747[Abstract/Free Full Text]
341. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, Weryha G, Duprez A, Leclere J 1999 Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 161:41–49[Abstract]
342. Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ 1998 Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 157:5–12[Abstract]
343. Katoh R, Miyagi E, Kawaoi A, Hemmi A, Komiyama A, Oyama T, Shibuya M 1999 Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol 30:891–897[CrossRef][Medline]
344. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I 1999 Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967–1976[Abstract/Free Full Text]
345. Shushanov S, Bronstein M, Adelaide J, Jussila L, Tchipysheva T, Jacquemier J, Stavrovskaya A, Birnbaum D, Karamysheva A 2000 VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer 86:47–52[CrossRef][Medline]
346. Fellmer PT, Sato K, Tanaka R, Okamoto T, Kato Y, Kobayashi M, Shibuya M, Obara T 1999 Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery 126:1056–1061[CrossRef][Medline]
347. Belletti B, Ferraro P, Arra C, Baldassarre G, Bruni P, Staibano S, De-Rosa G, Salvatore G, Fusco A, Persico MG, Viglietto G 1999 Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene 18:4860–4869[CrossRef][Medline]
348. Klein M, Vignaud JM, Hennequin V, Tousainy B, Bresler B, Plenat F, LeClere J, Duprez A, Weryha G 2001 Increased expression of the vascular endothelial growth factor is a pejorative marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86:656–658[Abstract/Free Full Text]
349. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL 2000 The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 10:349–357[Medline]
350. McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD, Ball DW, Baylin SB, Nelkin BD 1999 Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci USA 96:4540–4545[Abstract/Free Full Text]
351. Eggo MC, Hopkins JM, Franklyn JA, Johnson GD, Sanders DS, Sheppard MC 1995 Expression of fibroblast growth factors in thyroid cancer. J Clin Endocrinol Metab 80:1006–1011[Abstract]
352. Shingu K, Fujimori M, Ito K, Hama Y, Kasuga Y, Kobayashi S, Itoh N, Amano J 1998 Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions. Endocr J 45:35–43[Medline]
353. Logan A, Black EG, Gonzalez AM, Buscaglia M, Sheppard MC 1992 Basic fibroblast growth factor: an autocrine mitogen of rat thyroid follicular cells? Endocrinology 130:2363–2372[Abstract/Free Full Text]
354. Emoto N, Onose H, Sugihara H, Minami S, Shimizu K, Wakabayashi I 1998 Fibroblast growth factor-2 free from extracellular matrix is increased in papillary thyroid carcinomas and Graves’ thyroids. Thyroid 8:491–497[Medline]
355. Patel VA, Hill DJ, Eggo MC, Sheppard MC, Becks GP, Logan A 1996 Changes in the immunohistochemical localisation of fibroblast growth factor-2, transforming growth factor-ß 1 and thrombospondin-1 are associated with early angiogenic events in the hyperplastic rat thyroid. J Endocrinol 148:485–499[Abstract/Free Full Text]
356. Thompson SD, Franklyn JA, Watkinson JC, Verhaeg JM, Sheppard MC, Eggo MC 1998 Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia. J Clin Endocrinol Metab 83:1336–1341[Abstract/Free Full Text]
357. Scarpino S, Stoppacciaro A, Colarossi C, Cancellario F, Marzullo A, Marchesi M, Biffoni M, Comoglio PM, Prat M, Ruco LP 1999 Hepatocyte growth factor (HGF) stimulates tumor invasiveness in papillary carcinoma of the thyroid. J Pathol 189:570–575[CrossRef][Medline]
358. Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, Hattey E, Mildner M, Weninger W, Nakamura T, Tschachler E, Binder BR 1999 Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 79:427–438[Medline]
359. de Luca A, Arena N, Sena LM, Medico E 1999 Met overexpression confers HGF-dependent invasive phenotype to human thyroid carcinoma cells in vitro. J Cell Physiol 180:365–371[CrossRef][Medline]
360. Belfiore A, Gangemi P, Costantino A, Russo G, Santonocito GM, Ippolito O, Di Renzo MF, Comoglio P, Fiumara A, Vigneri R 1997 Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab 82:2322–2328[Abstract/Free Full Text]
361. Trovato M, Villari D, Bartolone L, Spinella S, Simone A, Violi MA, Trimarchi F, Batolo D, Benvenga S 1998 Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid 8:125–131[Medline]
362. Trovato M, Fraggetta F, Villari D, Batolo D, Mackey K, Trimarchi F, Benvenga S 1999 Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. J Clin Endocrinol Metab 84:3235–3240[Abstract/Free Full Text]
363. Zanetti A, Stoppacciaro A, Marzullo A, Ciabatta M, Fazioli F, Prat M, Comoglio PM, Baroni CD, Ruco LP 1998 Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. J Pathol 186:287–291[CrossRef][Medline]
364. Oyama T, Ichimura E, Sano T, Kashiwabara K, Fukuda T, Nakajima T 1998 c-Met expression of thyroid tissue with special reference to papillary carcinoma. Pathol Int 48:763–768[Medline]
365. Ivan M, Bond JA, Prat M, Comoglio PM, Wynford Thomas D 1997 Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14:2417–2423[CrossRef][Medline]
366. Aust G, Hofmann A, Laue S, Rost A, Kohler T, Scherbaum WA 1997 Human thyroid carcinoma cell lines and normal thyrocytes: expression and regulation of matrix metalloproteinase-1 and tissue matrix metalloproteinase inhibitor-1 messenger-RNA and protein. Thyroid 7:713–724[Medline]
367. Korem S, Resnick MB, Kraiem Z 1999 Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells. J Clin Endocrinol Metab 84:3322–3327[Abstract/Free Full Text]
368. Kameyama K 1996 Expression of MMP-1 in the capsule of thyroid cancer—relationship with invasiveness. Pathol Res Pract 192:20–26[Medline]
369. Campo E, Merino MJ, Liotta L, Neumann R, Stetler-Stevenson W 1992 Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 23:1395–1401[CrossRef][Medline]
370. Nakamura H, Ueno H, Yamashita K, Shimada T, Yamamoto E, Noguchi M, Fujimoto N, Sato H, Seiki M, Okada Y 1999 Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 59:467–473[Abstract/Free Full Text]
371. Hofmann A, Laue S, Rost AK, Scherbaum WA, Aust G 1998 mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. Thyroid 8:203–214[Medline]
372. Smit JW, van der Pluijm G, Romijn HA, Lowik CW, Morreau H, Goslings BM 1999 Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. Thyroid 9:913–919[Medline]
373. Hama Y, Shimizu T, Hosaka S, Sugenoya A, Usuda N 1997 Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. Exp Toxicol Pathol 49:239–247[Medline]
374. Kebebew E, Wong MG, Siperstein AE, Duh QY, Clark OH 1999 Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function. J Clin Endocrinol Metab 848:2840–2847
375. Narimatsu M, Nagayama Y, Akino K, Yasuda M, Yamamoto T, Yang T, Ohtsuru A, Namba H, Yamashita S, Ayabe H, Niwa M 1988 Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab 83:3668–3672
376. Nagayama Y, Shigetematsu K, Namba H, Zeki K, Yamashita S, Niwa M 2000 Inhibition of angiogenesis and tumorigenesis and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Res 20:2723–2728[Medline]
377. Saxe AW 1984 Angiogenesis of human parathyroid tissue. Surgery 96:1138–1143[Medline]
378. Carter WB, Crowell SL, Boswell CA, Williams SK 1996 Stimulation of angiogenesis by canine parathyroid tissue. Surgery 120:1089–1094[CrossRef][Medline]
379. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB 1995 Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95:2047–2053
380. Chudek J, Ritz E, Kovacs G 1998 Genetic abnormalities in parathyroid nodules of uremic patients. Clin Cancer Res 4:211–214[Abstract]
381. D’Adda T, Amorosi A, Bussolati G, Brandi ML, Bordi C 1993 Proliferation of endothelial component of parathyroid gland in multiple endocrine neoplasia type 1. Potential relationship with a mitogenic factor. Am J Pathol 143:612–617[Abstract]
382. Benvenuti S, Masi L, Falchetti A, Mancini L, Formigli L, Zecchi S, Amorosi A, Tonelli F, Brandi ML 1997 HPE cells: a clonal endothelial cell line established from human parathyroid tissue (human parathyroid cell line). Endothelium 5:37–49[Medline]
383. Lambert D, Eaton CL, Harrison BJ 1998 Fibroblast growth factors and their receptors in parathyroid disease. World J Surg 22:520–525[CrossRef][Medline]
384. Komatsu M, Tsuchiya S, Matsuyama I, Kaneko S, Suzuki Y, Ito N, Hanamura N, Seki T, Kobayashi S, Kuroda T 1994 Expression of basic fibroblast growth factor in hyperplastic parathyroid glands from patients with multiple endocrine neoplasia type I. World J Surg 18:921–924[CrossRef][Medline]
385. Brandi ML 1990 A novel endothelial cell growth factor circulates in familial multiple endocrine neoplasia type 1. Int J Rad Appl Instrum B 17:639–643[Medline]
386. Tanaka R, Tsushima T, Murakami H, Shizume K, Obara T 1994 Insulin-like growth factor I receptors and insulin-like growth factor-binding proteins in human parathyroid tumors. World J Surg 18:635–641[CrossRef][Medline]
387. Sadler GP, Jones DL, Woodhead JS, Horgan K, Wheeler MH 1996 Effect of growth factors on growth of bovine parathyroid cells in serum-free medium. World J Surg 20:822–828[CrossRef][Medline]
388. Kvasnicka T, Wang W, Johansson H, Sandelin K, Grimelius L 1997 Apoptosis and growth factors in parathyroid adenomas. Horm Metab Res 29:544–548[Medline]
389. Gogusev J, Duchambon P, Stoermann-Chopard C, Giovannini M, Sarfati E, Drueke TB 1996 De novo expression of transforming growth factor- in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. Nephrol Dial Transplant 11:2155–2162[Abstract/Free Full Text]
390. Sadler GP, Morgan JM, Jasani B, Douglas-Jones A, Wheeler MH 1996 Epidermal growth factor receptor status in hyperparathyroidism: immunocytochemical and in situ hybridization study. World J Surg 20:736–742[CrossRef][Medline]
391. Farnebo F, The BT, Dotzenrath C, Wassif WS, Svensson A, White I, Betz R, Goretzki P, Sandelin K, Farenbo LO, Larsson C 1997 Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism. Hum Genet 99:342–349[CrossRef][Medline]
392. Tahara H, Smith AP, Gaz RD, Arnold A 1996 Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. J Clin Endocrinol Metab 81:3663–3667[Abstract]
393. Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS, Arnold A 1998 Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 83:1766–1770[Abstract/Free Full Text]
394. Dwight T, Twigg S, Delbridge L, Wong FK, Farnebo F, Richardson AL, Nelson A, Zedenius J, Philips J, Larsson C, The BT, Robinson B 2000 Loss of heterozygosity in sporadic parathyroid tumors: involvement of chromosome 1 and the MEN1 gene locus in 11q13. Clin Endocrinol (Oxf) 53:85–92[CrossRef][Medline]
395. Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL, Arnold A 1991 PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88:9638–9642[Abstract/Free Full Text]
396. Rosenberg CL, Motokura T, Kronenberg HM, Arnold A 1993 Coding sequence of the overexpressed transcript of the putative oncogene PRAD1/cyclin D1 in two primary human tumors. Oncogene 8:519–521[Medline]
397. Williamson C, Pannett AA, Pang JT, Wooding C, McCarthy M, Sheppard MN, Monson J, Clayton RN, Thakker RV 1997 Localisation of a gene causing endocrine neoplasia to a 4 cM region on chromosome 1p35–p36. J Med Genet 34:617–619[Abstract/Free Full Text]
398. Salimath B, Marme D, Finkenzeller G 2000 Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene 19:3470–3476[CrossRef][Medline]
399. Boon LM, Brouillard P, Irrthum A, Karttunen L, Warman ML, Rudolph R, Mulliken JB, Olsen BR, Vikkula M 1999 A gene for inherited cutaneous venous anomalies ("glomangiomas") localizes to chromosome 1p21–22. Am J Hum Genet 65:125–133[CrossRef][Medline]
400. Slodkowska J, Sikora J, Androsiuk W, Rudzinski P, Radomyski A 1999 Lung carcinoids. Tumor angiogenesis in relation to clinicopathologic characteristics. Anal Quant Cytol Histol 21:267–272[Medline]
401. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Flejou J, Degott C 1998 Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 32:133–138[CrossRef][Medline]
402. Beauchamp RD, Coffey Jr RJ, Lyons RM, Perkett EA, Townsend Jr CM, Moses HL 1991 Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res 51:5253–5260[Abstract/Free Full Text]
403. Cai YC, Barnard G, Hiestand L, Woda B, Colby J, Banner B 1997 Florid angiogenesis in mucosa surrounding an ileal carcinoid tumor expressing transforming growth factor-. Am J Surg Pathol 21:1373–1377[CrossRef][Medline]
404. Chaudhry A, Oberg K, Gobl A, Heldin CH, Funa K 1994 Expression of transforming growth factors ß 1, ß 2, ß 3 in neuroendocrine tumors of the digestive system. Anticancer Res 14:2085–2091[Medline]
405. Oberg-Welsh C, Sandler S, Andersson A, Welsh M 1997 Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro. Mol Cell Endocrinol 126:125–132[CrossRef][Medline]
406. Rooman I, Schuit F, Bouwens L 1997 Effect of vascular endothelial growth factor on growth and differentiation of pancreatic ductal epithelium. Lab Invest 76:225–232[Medline]
407. Kuroda M, Oka T, Oka Y, Yamochi T, Ohtsubo K, Mori S, Watanabe T, Machinami R, Ohnishi S 1995 Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. J Clin Endocrinol Metab 80:3196–3200[Abstract]
408. Konno H, Arai T, Tanaka T, Baba M, Matsumoto K, Kanai T, Nakamura S, Baba S, Naito Y, Sugimura H, Yukita A, Asano M, Suzuki H 1998 Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. Jpn J Cancer Res 89:933–939[Medline]

This article has been cited by other articles:

				C. Rodriguez-Antona, J. Pallares, C. Montero-Conde, L. Inglada-Perez, E. Castelblanco, I. Landa, S. Leskela, L. J Leandro-Garcia, E. Lopez-Jimenez, R. Leton, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis Endocr. Relat. Cancer, March 1, 2010; 17(1): 7 - 16. [Abstract] [Full Text] [PDF]

				B. Harding, M. C Lemos, A. A C Reed, G. V Walls, J. Jeyabalan, M. R Bowl, H. Tateossian, N. Sullivan, T. Hough, W. D Fraser, et al. Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia Endocr. Relat. Cancer, December 1, 2009; 16(4): 1313 - 1327. [Abstract] [Full Text] [PDF]

				N. Figueroa-Vega, P. Sanz-Cameno, R. Moreno-Otero, F. Sanchez-Madrid, R. Gonzalez-Amaro, and M. Marazuela Serum Levels of Angiogenic Molecules in Autoimmune Thyroid Diseases and Their Correlation with Laboratory and Clinical Features J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1145 - 1153. [Abstract] [Full Text] [PDF]

				R. T. Kloos, M. D. Ringel, M. V. Knopp, N. C. Hall, M. King, R. Stevens, J. Liang, P. E. Wakely Jr, V. V. Vasko, M. Saji, et al. Phase II Trial of Sorafenib in Metastatic Thyroid Cancer J. Clin. Oncol., April 1, 2009; 27(10): 1675 - 1684. [Abstract] [Full Text] [PDF]

				K. Raina, S. Rajamanickam, R. P. Singh, G. Deep, M. Chittezhath, and R. Agarwal Stage-Specific Inhibitory Effects and Associated Mechanisms of Silibinin on Tumor Progression and Metastasis in Transgenic Adenocarcinoma of the Mouse Prostate Model Cancer Res., August 15, 2008; 68(16): 6822 - 6830. [Abstract] [Full Text] [PDF]

				M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, et al. Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., July 10, 2008; 26(20): 3403 - 3410. [Abstract] [Full Text] [PDF]

				S. Balthasar, N. Bergelin, C. Lof, M. Vainio, S. Andersson, and K. Tornquist Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells Endocr. Relat. Cancer, June 1, 2008; 15(2): 521 - 534. [Abstract] [Full Text] [PDF]

				P. Vaupel Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis Oncologist, May 1, 2008; 13(suppl_3): 21 - 26. [Abstract] [Full Text] [PDF]

				N. Korsisaari, J. Ross, X. Wu, M. Kowanetz, N. Pal, L. Hall, J. Eastham-Anderson, W. F. Forrest, N. Van Bruggen, F. V. Peale, et al. Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1 Clin. Cancer Res., January 1, 2008; 14(1): 249 - 258. [Abstract] [Full Text] [PDF]

				P.-J. Hsiao, M.-Y. Lu, F.-Y. Chiang, S.-J. Shin, Y.-D. Tai, and S.-H. H. Juo Vascular endothelial growth factor gene polymorphisms in thyroid cancer J. Endocrinol., November 1, 2007; 195(2): 265 - 270. [Abstract] [Full Text] [PDF]

				J. Klubo-Gwiezdzinska, R. Junik, E. Kopczynska, O. Juraniec, and H. Kardymowicz The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter Eur. J. Endocrinol., October 1, 2007; 157(4): 521 - 527. [Abstract] [Full Text] [PDF]

				D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF]

				Y. Erbil, Y. Ozluk, M. Giris, A. Salmaslioglu, H. Issever, U. Barbaros, Y. Kapran, S. Ozarmagan, and S. Tezelman Effect of Lugol Solution on Thyroid Gland Blood Flow and Microvessel Density in the Patients with Graves' Disease J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2182 - 2189. [Abstract] [Full Text] [PDF]

				S. A. Boikos and C. A. Stratakis Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis Hum. Mol. Genet., April 15, 2007; 16(R1): R80 - R87. [Abstract] [Full Text] [PDF]

				R. Libe, A. Fratticci, and J. Bertherat Adrenocortical cancer: pathophysiology and clinical management Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28. [Abstract] [Full Text] [PDF]

				G. N. Naumov, R. S. Watnick, N. Almog, L. A. Akslen, and J. Folkman Response: Re: A Model of Human Tumor Dormancy: An Angiogenic Escape From the Nonangiogenic Phenotype J Natl Cancer Inst, February 21, 2007; 99(4): 331 - 332. [Full Text] [PDF]

				A. J Sarkar, K. Chaturvedi, C. P. Chen, and D. K Sarkar Changes in thrombospondin-1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors J. Endocrinol., February 1, 2007; 192(2): 395 - 403. [Abstract] [Full Text] [PDF]

				A. N. Paisley, C. J. O'Callaghan, K. C. Lewandowski, C. Parkinson, M. E. Roberts, W. M. Drake, J. P. Monson, P. J. Trainer, and H. S. Randeva Reductions of Circulating Matrix Metalloproteinase 2 and Vascular Endothelial Growth Factor Levels after Treatment with Pegvisomant in Subjects with Acromegaly J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4635 - 4640. [Abstract] [Full Text] [PDF]

				C. Onofri, M. Theodoropoulou, M. Losa, E. Uhl, M. Lange, E. Arzt, G. K Stalla, and U. Renner Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J. Endocrinol., October 1, 2006; 191(1): 249 - 261. [Abstract] [Full Text] [PDF]

				U. Ohnemus, M. Uenalan, J. Inzunza, J.-A. Gustafsson, and R. Paus The Hair Follicle as an Estrogen Target and Source Endocr. Rev., October 1, 2006; 27(6): 677 - 706. [Abstract] [Full Text] [PDF]

				D. W. Kim, Y. S. Jo, H. S. Jung, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, J. H. Hwang, S. Y. Rha, G. R. Kweon, et al. An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4070 - 4076. [Abstract] [Full Text] [PDF]

				R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]

				D. Pasquali, V. Rossi, S. Staibano, G. De Rosa, P. Chieffi, D. Prezioso, V. Mirone, M. Mascolo, D. Tramontano, A. Bellastella, et al. The Endocrine-Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF)/Prokineticin 1 and 2 and Receptor Expression in Human Prostate: Up-Regulation of EG-VEGF/Prokineticin 1 with Malignancy Endocrinology, September 1, 2006; 147(9): 4245 - 4251. [Abstract] [Full Text] [PDF]

				A. C Lazaris, S. Tseleni-Balafouta, T. Papathomas, T. Brousalis, G. Thomopoulou, G. Agrogiannis, and E. S Patsouris Immunohistochemical investigation of angiogenic factors in parathyroid proliferative lesions. Eur. J. Endocrinol., June 1, 2006; 154(6): 827 - 833. [Abstract] [Full Text] [PDF]

				G M Besser, P Burman, and A F Daly Predictors and rates of treatment-resistant tumor growth in acromegaly Eur. J. Endocrinol., August 1, 2005; 153(2): 187 - 193. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman Diagnosis and Management of Pituitary Carcinomas J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3089 - 3099. [Abstract] [Full Text] [PDF]

				V. M. Adhami, I. A. Siddiqui, N. Ahmad, S. Gupta, and H. Mukhtar Oral Consumption of Green Tea Polyphenols Inhibits Insulin-Like Growth Factor-I-Induced Signaling in an Autochthonous Mouse Model of Prostate Cancer Cancer Res., December 1, 2004; 64(23): 8715 - 8722. [Abstract] [Full Text] [PDF]

				N. Ferrara Vascular Endothelial Growth Factor: Basic Science and Clinical Progress Endocr. Rev., August 1, 2004; 25(4): 581 - 611. [Abstract] [Full Text] [PDF]

				F. B. Davis, S. A. Mousa, L. O'Connor, S. Mohamed, H.-Y. Lin, H. J. Cao, and P. J. Davis Proangiogenic Action of Thyroid Hormone Is Fibroblast Growth Factor-Dependent and Is Initiated at the Cell Surface Circ. Res., June 11, 2004; 94(11): 1500 - 1506. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Turner, H. E. Articles by Wass, J. A. H. Search for Related Content PubMed PubMed Citation Articles by Turner, H. E. Articles by Wass, J. A. H.